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Chapter 1
Introduction
The focus of this study is on fatigue, sleep disturbances and depression 
in patients with Parkinson’s disease and their impact on quality of life 
and how they are related to each other. In this introductory chapter a 
description of Parkinson’s disease is given, followed by information on 
its consequences for patients‘ quality of life in a theoretical model. The 
research questions are then formulated, and the chapter ends with an 
outline of the thesis.
1.1  Parkinson’s disease: a general picture
1.1.1 Historical  background
Parkinson’s disease (PD) was ﬁ  rst described by James Parkinson (1755-
1824) in 1817, a surgeon, working in London (1). In his words, the disease is 
characterized by “involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; with a propensity 
to bend the trunk forward, and to pass from a walking to a running 
pace, the senses and intellect being uninjured” (2). He described the 
slow progression of the disease, with prominent trembling in some body 
parts, the strange posture (this being most observable whilst walking, 
but sometimes whilst sitting or standing) or the slowness of movement, 
which unduly stresses the reduction in muscular power. Strangely, his 
essay contains no reference to rigidity, a symptom which was added by 
Charcot some sixty years later (3). Parkinson described in the hands of the 
six cases analyzed in the Shaking Palsy the start hesitation – the problems 
of initiating movements and subsequent falls. He managed to describe the 
impact on the reduction of daily living activities like writing, reading and 
eating. “As the disease proceeds, employments are accomplished with 
considerable difﬁ  culty, the hand failing to answer with exactness to the 
dictates of the will … writing now can be hardly at all accomplished; and 
reading, form the tremulous motion, is accomplished with some difﬁ  culty 
… whilst at meals the fork not being duly directed frequently fails to raise 
the morsel from the plate: which, when seized, is with much difﬁ  culty 
conveyed to the mouth.”
Currently recognized nonmotor features were reported anecdotally 
by him, but even he managed to recognize sleep disturbances (“the 
tremulous motions of the limbs occur during sleep, and augment until 
they awaken the patients, and frequently with much agitation and alarm”), 10 CHAPTER  1 10
bowel constipation (“the bowels … demand stimulating medicines of 
very considerable power”), swallowing problems, salivation problems, 
delirium or extreme exhaustion. In his cases he also described the fatigue 
of the extremities – weakness was more pronounced and also started 
earlier in the upper extremities when compared with the lower ones. 
1.1.2 Pathology
Parkinson’s disease (PD) is deﬁ   ned as a slowly progressive 
neurodegenerative disorder with no identiﬁ  able cause. PD is characterized 
by loss of pigmented neurons and gliosis, most prominently in the 
substantia nigra and locus coeruleus, and by the presence of Lewy bodies 
in degenerating neurons (4). The underlying neuronal degeneration 
in PD is believed to occur slowly in the decades preceding the onset of 
the symptoms. (5). Recent research in PD pathology has brought a new 
concept of PD – the neuronal changes are distributed not only in the 
structures of basal ganglia but throughout the entire nervous system 
– not only the central but also the peripheral and the enteric nervous 
systems (CNS, PNS, ENS). As a result, PD has come to be acknowledged 
as more than a monosystemic disorder with preferential obliteration of 
nigral dopaminergic neurons (6). The primary pathological changes in PD 
include inclusions of  -synuclein (Lewy bodies), and the presence of these 
aggregations (Lewy body pathology) is mandatory for the neuropathologic 
conﬁ  rmation of the clinical diagnosis.
As in nearly every illness, individuals cross from a subclinical 
phase to a symptomatic manifestation. Up to 80% of dopaminergic 
neurons are already lost before the ﬁ  rst clinical symptoms of PD appear. 
Neuropathologically spoken – clinical and preclinical manifestation could 
be differentiated from each other by virtue of changes in the topographic 
distribution pattern. Each stage displays newly affected regions in addition 
to those involved in previous stages (Figure 1.1 and 1.2). Physical contacts 
between susceptible regions may play a key role in the pathogenesis of PD, 
since all of the vulnerable nerve cells are closely interconnected projection 
neurons with a long and sparingly myelinated axon. In fact, routes do exist 
that would permit the propagation of the pathologic process in sporadic 
PD via retrograde axonal transport and transsynaptic transmission of a 
still indeterminate pathogen (7).
Since diagnosis in living subjects is based entirely on neurological 
examination and no antemortem biological marker exists, it is common 
for patients with PD to receive their diagnosis quite late in the disease 
process, or for some patients to be misdiagnosed. Due to all of these 
factors, it is difﬁ  cult to perform epidemiological studies in PD. 11
Fig 1.1 Schematic diagrams of the progression of the PD pathological process (7) 
Braak en Del explained this figure as follows: “Schematic diagrams showing the caudo-rostral 
progression of the PD-related pathological process (white and red arrows). The earliest predilection sites 
in persons with stage 1 inclusions are the dorsal motor nucleus of the vagal nerve and anterior olfactory 
structures (black arrows)” (7). in text
1.1.3 Epidemiology
Idiopathic Parkinson’s disease is observed in all countries, all ethnic groups 
and all socioeconomic classes. The prevalence of PD in industrialized 
countries is generally estimated at 0.1-0.3% of the entire population, 
although the prevalence in Africans or Asians is less compared with 
whites (one-third to one-half) (8). In industrialized countries reported 
incidence rates of PD are 11-18 per 100,000 person-years (9). The incidence 
in all European countries where vital statistics are kept is similar. The 
incidence of PD is larger in men than in women in every decade of life 
(10). This gender difference is explained by a theory of estrogen protection 
from neurodegeneration (11), although its role is still controversial. 12 CHAPTER  1
Fig. 1.2 Diagram of presymptomatic and symptomatic phases in PD (7)
Braak en Del explain this figure as follows: “Spatio Spatio-temporal diagram showing proposed 
presymptomatic and symptomatic phases in sporadic PD together with major subdivisions of the cerebral 
cortex and limbic loop (entorhinal region, hippocampal formation, amygdala), as well as involved 
lower brainstem nuclei. Uninvolved areas appear in white. The superordinate centers of the limbic (and 
striatal) loops undergo the most damage in sporadic PD. Note how the pathological process successively 
encroaches upon interconnected subcortical nuclei and cortical areas.” (7)13
PD is characterized by motor problems” the typical tetrad of hypo- 
and bradykinesia, resting tremor, postural instability and rigidity are the 
core features of Parkinson’s disease (12). The overall course of the disease 
is quite variable. In the majority of patients, the mean period of time from 
inception of the disease to a chairbound state is 7.5 years, but again, with 
a wide range (13,14). On the other hand, as many as one-third of cases are 
relatively mild and such patients may remain stable for 10 years or more.
1.1.4 Treatment
Currently there is no cure for PD, and no existing therapy has been 
shown clearly to slow down or reverse the progression of the disease. 
The most important goals of management are thus to preserve functional 
independence and health-related quality of life (HRQOL). Toward this 
end, treatment is directed at providing symptomatic relief for both motor 
and nonmotor symptoms while minimizing undue adverse effects. 
However, this approach has proven to be problematic in practice. 
The most effective therapy for treating motor symptoms, levodopa, has 
been associated with an increased risk of motor complications (15). These 
motor ﬂ  uctuations can impair HRQOL and cause signiﬁ  cant functional 
and social disability, directly contrary to the management goals. 
Before 1918, treatment was primarily supportive, but an epidemic 
of encephalitis, with its postencephalitic form of parkinsonism, led to the 
pursuit of effective therapies, ﬁ  rst of all for vaccine development and later 
towards symptomatic therapy. A number of natural remedies had been 
tried – Charcot described the use of extracts of Bulgarian belladonna and 
atropine, which were initially received with great promise, but which fell 
short of expectations. By the early 1950, synthetic drugs became available 
to treat symptoms of PD, but with serious side effects. 
The revolution in the treatment of PD started when levodopa was 
introduced into clinical practice in 1970s. Levodopa has become the 
cornerstone of symptomatic therapy. It is a precursor of the neurotransmitter 
dopamine. Its use emerged after various researchers in the late 1950s and 
1960s demonstrated that dopamine depletion was characteristic for PD. 
Levodopa is still regarded as the most potent symptomatic therapy for 
PD, bringing in a ‘honeymoon’ period when started. But there is a catch in 
its use: Late complications such as motor ﬂ  uctuations and dyskinesias are 
associated with chronic administration. To avoid these problems or at least 
to minimize them, other therapeutical possibilities have been studied. 
Dopamine agonists have been used to treat symptoms of PD since 
the late 1970s, initially to supplement the beneﬁ  ciary effect of levodopa. 
Recent research and methodological investigations have demonstrated 
therapeutical beneﬁ  t in all stages of PD, both in combination with levodopa 
and as a form of monotherapy. 14 CHAPTER  1
Monoamine oxidase inhibitors were discovered in 1950 and were 
ﬁ  rst utilized in the treatment of depression. Monoamine oxidase (MAO) 
is an enzyme involved in the breakdown of catecholamines, including 
dopamine. Only after the discovery of the two types of MAO, A and B, 
did MAO-B inhibitors started to be widely used in PD. Currently their 
neuroprotective properties are being studied and being proved in vitro, 
but unfortunately not in vivo. In clinical practice they are used as a 
monotherapy or as adjunctive therapy to levodopa.
Catechol-O-methyltransferase (COMT) is another enzyme involved 
in the metabolic pathways of dopamine. Second-generation COMT 
inhibitors were introduced in the 1990s, and they were more potent, 
more selective and less toxic than their predecessors. They are currently 
available for use as adjunctive therapy in patients who have developed 
motor ﬂ  uctuations. 
Amantadine was initially marked in the 1960s as an antiviral agent. It 
was used for several decades as therapy for PD, though current guidelines 
for PD treatment are inconsistent for how to use, or even whether to use this 
drug. Amantadine is used mostly as adjunctive therapy and occasionally 
in early monotherapy.
Anticholinergics are among the earliest class of pharmaceuticals 
used for the management of PD. In 1940 synthetic anticholinergics were 
introduced, replacing herbal preparations. With recent developments 
they have been moved to a less prominent role, because of their important 
side effects in susceptible individuals such as the elderly. 
Agents with novel mechanisms of action are currently being 
developed with the aim of inhibiting programmed cell death, maintaining 
mitochondrial membrane potential with the reduction of oxidative 
damage or promoting the survival or regeneration of dopaminergic 
neurons. Adenosine receptors antagonist, activators of c-Jun N-terminal 
kinase (JNK), the aminomethyl chromane chemical group of drugs, or 
glial-derived neurotrophic factor (GDNF) all belong to this potential 
treatment. 
The ideal drug for treating PD remains to be discovered, and 
signiﬁ  cant advances are not envisaged in the near future. To have a 
major place among the already existing treatment methods, a new agent 
should have the following characteristics: (a) antiparkinsonian efﬁ  cacy 
comparable to levodopa, (b) efﬁ  cacy against dopa-resistant symptoms, (c) 
free of motor (dyskinesias) and psychiatric (i.e. hallucinations, delirium, 
psychosis) side effects, (d) quick start of action, (e) good initial tolerability 
and (f) easy and convenient to administer (16). Use of the most effective 
modalities for PD treatment and the optimization of this treatment, as 
well as effective treatment of nonmotor symptoms, can lead to improved 
functionality and HRQOL in a patient.15
1.2  Parkinson’s disease: Nonmotor dysfunction 
James Parkinson accurately described the motor problems. Although he 
mentioned some nonmotor features of Parkinson’s disease, for a long 
time Parkinson’s disease was considered to be a disease with only motor 
features. Only in recent times have nonmotor features been noticed and 
become an inseparable element of PD.
Depression, anxiety, psychosis, apathy are among the most 
characteristic features of neuropsychiatric impairment of PD patients (17). 
Sleep problems, sexual dysfunction, falls, fatigue, autonomic dysfunction, 
olfactory problems, weight loss, sensory symptoms or cognitive 
impairment are other important nonmotor presentations of PD. These 
nonmotor symptoms contribute signiﬁ  cantly to worse Health Related 
Quality of Life (HRQoL). 
Some of nonmotor symptoms (NMS) are treatable if they are detected 
early (constipation, depression, sleep disturbances, anxiety, nausea) (18), 
though some may not be detected unless speciﬁ  cally tested for, like sexual 
problems, diplopia, olfactory dysfunction and weight change (18). These 
nonmotor problems are the result of dopamine dysregulation, but also 
may result from the non-dopaminergic-cell dysfunction (adrenergic, 
noradrenergic, serotoninergic, cholinergic) of the pathways not involved in 
motor function (17). This could also explain why these symptoms respond 
poorly, if at all, to a standard antiparkinsonian treatment. Recognition and 
treatment of NMS is an important part of modern and comprehensive 
healthcare for PD patients (18). 
1.2.1 Sleep  disturbances
Virtually all patients with Parkinson’s disease experience sleep disruption (17).
a) Nocturnal symptoms
Previous studies have shown that nocturnal symptoms usually begin early 
in the disease course (19). Degeneration of central sleep regulation centers 
in the brainstem and the thalamocortical pathways is probably responsible 
(19). Parkinson’s disease patients have been reported to have an abnormal 
sleep architecture, sleep disordered breathing due to obstructive sleep 
apnoea and a narcoleptic pattern of rapid onset of sleep (17). Nocturnal 
problems could be categorized subjectively as insomnia, motor, urinary 
and neuropsychiatric problems (19). 
Restless Legs syndrome (RLS), Periodic Limb Movement disorder 
(PLMD) and REM Sleep Behavior Disorder (RBD) belong to the group 
of parasomnias that frequently occur in PD patients. RLS is marked by 
an urge to move accompanied by dysesthesias in the limbs that occurs at 
rest alleviated by movement. Symptoms occur in a circadian pattern, with 
onset usually in the evening hours when lying in bed to go to sleep. PLMD 16 CHAPTER  1
may occur in association with RLS or independently. RLS and PLMD can 
both cause sleep disruption in PD patients and have been reported in 
some studies to show increased prevalence in PD (20).
REM behavior disorder (RBD) is a sleep disorder characterized by 
the occurrence of muscle activity during REM sleep with the occurrence 
of complex, vigorous, and sometimes violent behaviors (21). Patients and 
bedpartners have sustained lacerations and sometimes even fractures 
and dislocations as a result. RBD is present in 25 to 50% of PD patients. 
There have been no controlled studies of treatment interventions for 
RBD. In many patients, pharmacologic intervention for RBD may not be 
necessary if symptoms are mild and intermittent. In cases where behavior 
is more violent, putting either the patient or the caregiver at risk for injury, 
protective measures and treatment are indicated.
b) Excessive daytime sleepiness
Sleepiness is a ubiquitous phenomenon, experienced not only as a 
symptom in a number of medical, psychiatric and primary sleep disorders, 
but also as a normal physiological state by most individuals over any given 
24 hour period. Sleepiness can be considered abnormal when it occurs 
at inappropriate times, or does not occur when desired (22). Excessive 
daytime sleepiness (EDS) affects up to 50% of patients with PD and could 
be also a preclinical marker (17). 
EDS has been associated with more severe PD, greater PD-related 
disability, cognitive decline, more frequent hallucinations and a longer 
duration of levodopa therapy. Factors associated with development of 
EDS included dementia and a more rapid progression of parkinsonism 
(23). Other factors associated with EDS include the severity of PD and 
the duration of dopaminergic treatment (24). Several studies using 
polysomnography and the Multiple Sleep Latency Test (MSLT) suggest 
that daytime sleepiness may be a primary feature of PD and unrelated 
to PD treatments or nocturnal sleep disturbance (25,26). The current 
hypothesis is that sleepiness or a susceptibility to EDS may be an integral 
part of PD, reﬂ  ecting the extent of the neurodegenerative process.
1.2.2 Fatigue
Fatigue is a common problem in virtually all chronic medical and many 
psychiatric disorders (27). Yet, research on the nature and treatment of 
fatigue has been challenging for several reasons. First, fatigue is experienced 
on a continuum that includes both a normal state and a pathological 
disturbance. What constitutes problematic fatigue for one person may not 
be for another, so that the notion of personal expectation may also play a 
role. Fatigue also occurs in several independent conditions that are often 
comorbid with the disorder being studied, such as sleep dysfunction, or 
it may be caused by medications. Finally, fatigue is one of the symptoms 17
included in the criteria for diagnoses of anxiety and depressive disorders 
(27).
Recognition of fatigue as a common problem in Parkinson’s disease 
(PD) has occurred relatively recently. The ﬁ  rst papers on fatigue in PD 
were published in 1993 (28,29). The lack of recognition of fatigue as an 
important symptom in PD is reﬂ  ected in its absence from the Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) (30). So far, the understanding 
of fatigue in PD is in its early stages. Its impact in PD is generally 
underappreciated, and its treatment is empiric (31). 
1.2.3 Depression
Depression is a common neuropsychiatric feature of PD and may be more 
common in PD than in other conditions with similar levels of disability 
(15). This type of depression is often associated with increased disability, 
a worse HRQOL, more rapid progression of motor impairment/disability 
and an increased mortality hazard ratio (2.66) (32,33). The prevalence 
of depression in PD ranges from 20% to 50% (32,33). Between 5% and 
20% of these patients are diagnosed with major depression, with the 
remainder classiﬁ  ed as nonmajor depression, including minor depression, 
subsyndromal depression and dysthymia (34). 
Risk factors for depression in PD include an increased severity 
of cognitive impairment, female sex, possibly early-onset PD and a 
personal history of depression before diagnosis of PD (34). Depression is 
seen in all stages of PD and may be present prior to the onset of motor 
symptoms (35). Whether depression in PD is “reactive” or related solely to 
neuropathology is somewhat controversial. Most lines of evidence suggest 
a biological basis, stemming partly from studies that show a relationship 
between a history of depression and subsequent development of PD (17). 
Depression in PD is most likely related to a combination of neurobiologic 
and psychologic factors (34).
Of importance to managed care are recent studies that have 
underscored the lack of recognition and appropriate treatment of 
depression in PD (31,36). Most patients meeting the criteria for depression 
are not being treated or may be receiving suboptimal or ineffective 
treatment (36). This can lead to a rise in healthcare costs related to ongoing 
disability. A simple, reliable, routine screening method for depression in 
PD is needed, as well as the best treatment strategies.
1.2.4 Anxiety
Anxiety in PD has not been as well studied as depression. However, the 
majority of patients with depression will also meet criteria for an anxiety 
disorder and vice versa (34). Anxiety can be associated with greater 
physical and psychological distress than depression in PD.18 CHAPTER  1
Anxiety disorders in PD can be categorized as generalized anxiety 
disorder, panic disorder, social phobia and obsessive-compulsive disorder 
(OCD). Generalized anxiety disorder and panic attacks are the most 
common manifestations. While patients often try to avoid being seen in 
public places due to fear of embarrassment, this does not qualify for the 
diagnosis of social phobia. 
There is some evidence that generalized anxiety or panic attacks in 
PD are a reaction to the distressing components of the disease (e.g., to the 
discomfort and fear of loss of motor control) (33). However, many specialists 
feel that both psychosocial and neuropathologic factors are contributory 
(37). Patients with PD should be screened for anxiety disorders. 
1.3  The impact of Parkinson’s disease on patients` life 
Parkinson’s disease has a severe impact on an individual’s life, increasingly 
reducing the quality of life of PD patients (38-40). Patients with PD have 
worse QoL scores compared to the general population, whether measured 
using a generic or by a disease-speciﬁ  c instrument. Schrag et al. in a 
community-based cross sectional study of patients with PD showed worse 
health-related QoL in different domains – in mobility, activities of daily 
living, physical and social functioning, cognition, communication, bodily 
discomfort and emotional well-being (39). 
Reduced QoL was associated with various clinical and psychosocial 
variables: disease severity (40), motor complications of levodopa therapy 
(38,41), sleep problems (42), pain (43), depression (40) and cognitive 
impairment (44). Karlsen et al. found a signiﬁ  cant relationship between 
higher age and the physical mobility domain (45), while other studies 
did not report such a relationship (44). Longer disease duration was a 
signiﬁ  cant predictor of worse QoL (41), and female gender was associated 
with worse QoL (46).
For chronic illnesses for which there is no cure, it is important to 
establish treatments that really makes people feel better. Thus, survival 
per se is no longer perceived to be the only end point; the goal is to 
improve, restore or preserve QoL. The QoL construct was introduced 
to more comprehensively evaluate the outcomes of a chronic disease or 
effects of treatment interventions (47,48).
The World Health Organization (WHO) deﬁ   nes QOL as an 
“individual’s perception of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, 
expectations, standards and concerns.” It is a broad-ranging concept 
affected by an individual’s physical health, psychological state, level of 
independence, social relationships and relationships towards the salient 
features of their environment (49).
Besides biological measures, other levels of clinical measurement 19
can be considered in clinical studies: impairments, disability and health-
related quality of life (HRQoL). Impairments are the direct organic 
manifestations of the disease, such as consciousness and paresis (50). 
Disability can be deﬁ  ned as limitations in carrying out activities of daily 
living, such as self-care, mobility and activities inside or outside the home 
(50). 
1.4 Conceptual  framework
The conceptual framework of this study follows the model proposed by 
the WHO: the International Classiﬁ  cation of Functioning, Disability and 
Health (ICF). The aim was to provide a framework for the description 
of health and health-related states of well-being. It is a biopsychosocial 
model integrating medical and social models reﬂ  ecting disability as an 
interaction between the features of the person (the medical model) and 
the features of the overall context in which person lives (the social model). 
It has the potential to be used by various disciplines dealing with health 
and healthcare – scientiﬁ  c, as well as educational, political or sociological 
ﬁ  elds – as it is likely to become the generally accepted classiﬁ  cation for 
describing functioning and health (50,51). 
The ICF is formed by two parts. Part I represents Functioning and 
Disability. This part includes 2 components: Body functions and structures, 
and Activities and participation. Part II covers Contextual factors, and 
includes components of environmental and personal factors. 
Body functions  •  are normal, physiological and psychological functions 
of body systems. Body structures represent the anatomical structure of 
the body – organs and systems of organs.
Activities and participation  •  covers the whole range of aspects for the 
fulﬁ  llment of the normal roles of an individual.
Environmental factors •   comprise all the surroundings of an individual. 
They are external to individuals and can have positive or negative 
inﬂ  uence on an individual’s performance as a member of a society, 
the capacity to execute tasks or on body functions or structure.
Personal factors  •  are the particular details of an individual’s life and 
comprise also factors that are not part of the health condition or health 
status like age, gender, race, education and lifestyle. 20 CHAPTER  1
Figure 1.3. Structure of the ICF (50)
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In contrast with previous models, the ICF has moved away from the 
model of “consequences of the disease”, representing now “components 
of health”. While previous models were “disability-oriented”, the ICF 
terminology is now more neutral. Disability is in the context of ICF 
considered as an umbrella term for impairments in body functions and 
structures, limitations in activities and restrictions in participation. The 
term ‘Handicap’ was thus skipped and replaced by ‘Activities’ and 
‘Participation’.21
Figure 1.4 The ICF model of disability and the interaction of concepts (50)
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1.5 Research  questions
On an individual level, Parkinson’s disease is a chronic progressive 
disease with a large impact on quality of life. Research on quality of life in 
PD has mostly focused on the typical motor aspects of PD and a variety of 
nonmedical, mostly sociodemographic, factors.
Newly recognized nonmotor features have given rise to a number of 
rather fundamental and conceptual questions – what is their origin – are 
they just a consequence of biochemical changes in the brain or do some 
other factors contribute to their development? What are the relationships 
between the separate nonmotor features - are they independent from each 
other, do they act simultaneously or do they inﬂ  uence one another? What 
kind of impact do they have on patients’ lives? Despite the fact that a great 
deal of research has begun in this ﬁ  eld, not enough is yet known to be able 
answer all of these questions.
Our research was conducted in order to evaluate medical and nonmedical 
variables, their interrelationships and their inﬂ  uence on QoL. Fatigue, 
depression, anxiety and sleep disorders became the focus of our research. 
As current knowledge lacks a comprehensive view on these nonmotor 
features, the main aim was to create a model of predictors of quality of life 
and to explore the relations between these nonmotor features of PD and to 22 CHAPTER  1
discuss their clinical consequences. Therefore the following questions in 
the population of PD patients are discussed.
1  Which medical and sociodemographic variables inﬂ  uence quality of 
life in PD patients? Is QoL affected by nonmotor symptoms?
2  Does an interrelationship exist between some nonmotor PD features?
These general research questions are speciﬁ  ed as follows:
1a  Is there a relationship between daytime and nighttime sleep distur-
bances and different QoL domains?
1b  How are different fatigue domains related to different QoL domains, 
and is there a difference between the physical and mental dimen-
sions of QoL? 
2  Is there a relationship between nighttime or daytime sleep problems 
and fatigue, or are they independent from each other? 
3a  Do mood disorders or comorbidities contribute to the development 
of fatigue? 
3b  Is there a causal relation between disease severity and depression 
and fatigue, and between depression and fatigue themselves? 
1.6 Study  design
The study was designed as cross-sectional in order to evaluate quality of 
life and biomedical and psychosocial variables linked to QoL in patients 
with Parkinson’s disease. The patients were recruited from the hospitals 
and outpatients departments in the East Slovakian region. Data collection 
started in February 2004 and ended in November 2005. All patients were 
diagnosed according to the United Kingdom Parkinson’s Disease Society 
Brain Clinical Criteria (52; 52). Exclusion criteria were deﬁ  ned as follows: 1. 
presence of dementia; 2. disease duration longer than 15 years; 3. presence 
of comorbidity associated with the fatigue variable.23
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Based on the database records of outpatient neurologists, 512 PD patients 
were invited to participate in our study. A total of 19 patients refused 
immediately, 20 did not wish to participate because of the severity of 
disease status and 263 did not respond to the invitation. Out of responders, 
7 patients did not meet inclusion criteria and 13 were excluded because 
of the missing data (these patients agreed to participate in the study, 
ﬁ  lled in the questionnaire, but refused to come for the oral interview); 190 
remained for analysis (See Figure 1.6.). Most of the patients were recruited 
from several outpatient departments over the eastern part of Slovakia. 
Figure 1.6 Data collection – details on responders and nonresponders of the total sample 
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The ﬁ  rst protocol did not include the sleep questionnaires, which were 
introduced into our study later. After both sleep questionnaires were added, 
218 patients were asked to participate. Fourteen refused immediately and 
91 did not respond to the invitation; 7 patients did not meet inclusion 
criteria, 13 were excluded because of missing data and consequently 93 
remained for analysis (See Figure 1.7.).
Figure 1.7 Data collection – details on responders and nonresponders of the sample after introduction of 
the sleep questionnaires
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Data were collected by means of a mailed questionnaire comprising 
questions on sociodemographic background, medical history and current 
medication, as well as self-report questionnaires. After three weeks 
all patients were interviewed with a structured interview and were 
examined by the same neurologist, who assessed functional status and 
mental abilities. Patients who were not able to ﬁ  ll in the questionnaires 
by themselves because of motor impairment of their hands answered the 
questions during an oral interview.
Nonresponders did not differ signiﬁ  cantly from the analyzed total 
group in age (mean difference, 1.9 yrs., SE=0.78; t=1.965; 95%CI 0.46 – 26 CHAPTER  1
3.54). Nonresponders in the group with the sleep questionnaires also did 
not differ signiﬁ  cantly from the analyzed group in age (mean difference 
1.6 yrs., SE=1.22; t=1.315; 95%CI -0.798 – 4.003) or gender (difference 
between proportions 0.095, SE = 0.066, 95% CI -0.0343–0.224) (difference 
of proportions test) (28). 
Table 1 Clinical and sociodemographic variables of the total study sample and the study sample with the 
sleep questionnaires
Total sample Sleep sub-sample
Variable n, %, Mean±SD n, %, Mean±SD
1. Gender 
Male  93 (48.9%) 46 (49.5%)
Female  97 (51.1%) 47 (50.5%)
2.  Age 68.2 ± 9.3 68.0 ± 9.5
3.  Disease duration 6.4 ± 4.7 6.1 ± 5.9
4.  UPDRS* total 36.3 ± 20.5 35.3 ± 20.4
UPDRS III 16.1 ± 10.7 15.6 ± 10.7
UPDRS IV 3.3 ± 3.3 3.1 ± 3.0
5. H Y* 2.2 ± 1.1 2.0 ± 1.2
≤ 2.0 115 (60.5%) 65 (69.9%)
> 2.0  75 (39.5%) 28 (30.1%)
6. S E* 69.3 ± 22.3 69.6 ± 22.1
≤ 70% 88 (46.3%) 41 (44.0%)
> 70% 102 (53.7%) 52 (56.0%)
7.  PSQI* 9.1 ± 4.9
≥ 5  68 (73.1%)
8.  ESS* 7.76 ± 4.9
> 10 22 (23.7%)
9.  Antiparkinsonian drugs used
L-dopa 24 (12.6%) 10 (10.7%)
Dopamine agonists 43 (22.6%) 21 (22.6%)
L-dopa + COMT inhibitors 40 (21.1%) 12 (12.9%)
L-dopa + Dopamine agonists 27 (14.2%) 8 (8.6%)
L-dopa + COMT inhibitor + Dopamine agonists 23 (12.1%) 6 (6.5%)
Other  33 (17.4%) 36 (38.7%)
*UPDRS - Unified Parkinson’s Disease Rating Scale. H Y - Hoehn   Yahr Staging. S E - Schwab   
England Scale. PSQI - Pittsburgh Sleep Quality Index. ESS - Epworth Sleepiness Scale
The study was approved by the Ethics Committee of the University Hospital Kosice on the 17th of 
December 2002. Informed consent was obtained from each patient. 27
1.7  Outline of the thesis
Nonmotor symptoms are common in patients with Parkinson’s disease. 
They are recognized as factors having a negative inﬂ  uence on quality of 
life, but the exact impact still remains unclear. Among all of the nonmotor 
symptoms, fatigue is one of the ﬁ  rst three most disabling problems when 
rated by PD patients, thus fatigue, together with quality of life, is at the 
centre of our research. 
Sleep problems, and especially sleepiness, started to attract attention 
after the reports of so called “sleep attacks” were connected with 
antiparkinsonian therapy (dopamine agonists) and it was determined that 
they could even lead to car accidents. The inﬂ  uence of excessive daytime 
sleepiness and poor night-time sleep on quality of life is described in 
Chapter 2. 
In Chapter 3 the inﬂ  uence of fatigue on quality of life is presented. 
Five different fatigue dimensions are evaluated in order to explore their 
impact on eight quality of life domains. Linear regression analysis was 
performed in a stepwise manner in two blocks; the ﬁ  rst block contained the 
variables that we controlled for (age, gender, disease duration, education 
level and disease severity) and the second block contained the ﬁ  ve fatigue 
domains. 
The aim of our research presented in Chapter 4 was to explore the 
relationship between sleep problems occurring either during daytime 
(excessive daytime sleepiness) or nighttime (quality of sleep) and fatigue. 
Series of linear regression were performed to evaluate separately sleepiness 
or sleep quality and their relationships with age, gender, disease duration, 
disease severity, depression and all separate fatigue domains.
The next chapters deal with fatigue and factors related to the 
development of fatigue in PD patients. In Chapter 5 the relative strength of 
disease duration, comorbidities, anxiety, depression and disease severity 
was explored in order to evaluate, using linear regression analysis, their 
inﬂ  uence on ﬁ  ve domains of fatigue: general fatigue, physical fatigue, 
reduced activity, reduced motivation and mental fatigue. The aim of 
Chapter 6 is to examine how disease severity explains the different fatigue 
domains, how disease severity explains depression, and how disease 
severity explains via depression the different fatigue domains using 
LISREL. 
In the last chapter (7) the consequences of our research and their 
potential impact on clinical practice are discussed. In addition, the possible 
interventions which could lead to improvements of the quality of life of 
PD patients are presented in this ﬁ  nal chapter. 28 CHAPTER  1
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Abstract
Background
Sleep disturbances are common and often severe in patients with 
Parkinson’s disease (PD) and can occur at any time of day. The purpose 
of our study was to examine how excessive daytime sleepiness or poor 
nocturnal sleep quality and mood disorders inﬂ  uence the quality of life 
(QoL) in PD patients. 
Methods
Ninety-three PD patients from Eastern Slovakia were recruited (49.5% 
males, mean age 68.0±9.5 years, mean disease duration 6.1±5.9 years). 
Sleep disturbances were measured using the Epworth Sleepiness Scale 
(ESS) and the Pittsburgh Sleep Quality Index (PSQI); QoL with the 
Parkinson’s Disease Quality of Life Questionnaire (PDQ-39); depression 
and anxiety with the Hospital Anxiety and Depression Scale (HADS) 
and disease severity with the Uniﬁ  ed Parkinson’s Disease Rating Scale 
(UPDRS).  2-test, bivariate correlations and multiple linear regressions 
were performed.
Results
PSQI and ESS had signiﬁ   cant associations with worse QoL (p<.01, 
p<.05, resp.). HADS-D (p<.01), HADS-A (p<.01), UPDRS (p<.01) and 
disease duration (p<.05) were also signiﬁ  cantly related to worse QoL. 
In the linear regression analysis, however, only PSQI (p<.01), anxiety 
(p<.001) and UPDRS (p<.001) remained signiﬁ  cant. The model with PSQI 
explained 82% of the variance, and the model with ESS explained 76% of 
the variance in PDQ-39 when analyses were performed separately. In an 
overall model, however, only PSQI remained signiﬁ  cant, accounting for 
82% of the variance in PDQ-39. 
Discussion
Nighttime poor sleep and anxiety are important contributors leading to a 
worse QoL. As these are treatable conditions, they should be recognized 
by clinicians, managed properly and thus used to improve the quality of 
life for PD patients. 
Key words:
Parkinson’s disease, quality of sleep, sleepiness, anxiety, depression, disease 
severity, quality of life35
The impact of sleep and mood disorders on quality of life in 
Parkinson’s disease patients
Introduction
Sleep disorders are common and often severe in patients with Parkinson’s 
disease (PD). They can occur at any time day or night. As many as 98% of 
PD patients suffer from nocturnal symptoms that can disturb their sleep [1]. 
Nighttime problems such as reduced total sleep time and sleep efﬁ  ciency 
and an increased number of sleep arousals and fragmentations of sleep 
have all been reported in PD patients [1]. Sleep disturbance correlates with 
disease severity, cognitive decline and pain. Depression is another factor 
strongly related to sleep problems [2]. Borek et al. found that poor quality 
of sleep also showed signiﬁ  cant correlations with elevated anxiety scores 
and longer duration of PD, but in their regression model only depression 
and sleep medication use were signiﬁ  cant predictors of poor sleep [3]. 
Excessive daytime sleepiness (EDS) was reported in approximately 
15% of PD patients, with an 8-year prevalence of 54% [4]. Its manifestation 
may be either rapid – so-called ‘sleep attacks’ – or slow, meaning patients 
may feel sleepy and slowly drift off to sleep [1]. If unrecognized and 
untreated, sleepiness can result in poor attention and memory and even 
in accidents. A study by Borek et al. found that EDS correlated with 
depression, anxiety, disease duration, male gender and use of dopamine 
agonists. In the linear regression model they found only anxiety, male 
gender and disease duration to be signiﬁ  cant predictors of EDS [3].
Patients with PD have lower Quality of Life (QoL) scores compared 
to the general population. Schrag et al. [5] and Karlsen et al. [6], using 
the Nottingham Health Proﬁ  le, reported worse scores in the emotional 
reactions, energy, pain, sleep, social isolation and physical mobility 
domains, social functioning, physical role limitations and general health 
perceptions. Various clinical and psychosocial variables have been 
evaluated with regard to QoL. Disease severity [7], motor complications 
[8,9], sleep problems [10], pain [11], depression [7,12], anxiety [13] and 
cognitive impairment [12] have all been found to signiﬁ  cantly worsen QoL. 
Karlsen et al. found a signiﬁ  cant relationship between higher age and the 
physical mobility domain [14], while other studies did not report such 
a relationship [6,12]. Longer disease duration was a signiﬁ  cant predictor 
of the worse QoL domains [8]. Female gender was also associated with 
worse QoL [15].
The aim of our study was to evaluate how sleep problems – poor quality 
of sleep or daytime somnolence, mood disorders and disease severity – 
affect quality of life, controlled for age, gender and disease duration.36 CHAPTER  2
Methods
Patients
This cross-sectional study evaluated quality of life and sleep disturbances 
in a study population of 93 patients with Parkinson’s disease. The patients 
were recruited from the hospitals and outpatient departments in the East 
Slovakian region between February 2004 and November 2005. All patients 
were diagnosed in accordance with the United Kingdom Parkinson’s 
Disease Society Brain Clinical Criteria [16] and their mental abilities were 
assessed with the Mini-Mental State Examination (MMSE) [17]. Exclusion 
criteria were deﬁ  ned as follows: 1. MMSE lower than 24; 2. presence of 
severe comorbidity associated with the study variables.
The study was approved by the local Ethics Committee. Informed 
consent was obtained from each patient prior to the study. 
Data collection 
Data were collected by means of a mailed questionnaire comprising 
questions on sociodemographic background, medical history and 
current medication, and self-report questionnaires: the Pittsburgh Sleep 
Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Hospital Anxiety 
and Depression Scale (HADS) and Parkinson`s Disease Quality of Life 
Questionnaire (PDQ-39). After three weeks, all patients were interviewed 
on relevant issues that were not part of the questionnaires. After this 
structured interview, a neurologist assessed the disease severity of each 
patient using the Uniﬁ   ed Parkinson’s Disease Rating Scale (UPDRS) 
Version 3.0 [18], including Hoehn and Yahr staging [19] and the Schwab 
and England disability scale [20]. Patients who were not able to ﬁ  ll in 
the questionnaires answered the questions during an oral interview. 
Caregivers were not allowed to provide questionnaires inputs.
Measures
Sleep disorders
The Pittsburgh Sleep Quality Index (PSQI) [21] was used to assess nighttime 
sleep problems. PSQI assesses global sleep quality and disturbances in 
sleep patterns during the previous month in seven components: subjective 
sleep quality, sleep latency, sleep duration, habitual sleep efﬁ  ciency, sleep 
disturbances, use of sleep medication and daytime dysfunction. Scoring 
of the answers ranges from 0 (no difﬁ  culty) to 3 (severe difﬁ  culty). After 
recoding, each component has possible scores of 0 – 3, where 3 indicates the 
negative extreme. The global PSQI score is the sum of all the component 
scores (range 0 – 21), with a score of 5 or more indicating a poor sleeper. 
This instrument was found to have good internal consistency, with a 
Cronbach’s alpha coefﬁ  cient of 0.81 in our sample. 37
For evaluation of daytime somnolence the Epworth Sleepiness Scale 
(ESS) [22] was used. ESS relies on measuring dozing behavior in eight 
different situations. The questionnaire asks the respondent to rate the 
likelihood of falling asleep on a scale from 0 to 3, were 0 indicates no 
chance and 3 represents the greatest chance of dozing. The total ESS score 
is the sum of all the responses and ranges from 0 to 24, higher scores reﬂ  ect 
a greater propensity for sleep. A score of 10 was used as the cutoff point 
for normal, while scores above this imply pathological sleepiness [23]. 
This instrument has been found to have good psychometric properties in 
PD patients [24]. In our sample we also found good internal consistency, 
with a Cronbach’s alpha coefﬁ  cient of 0.84 
Mood disorders
Depression and anxiety were assessed using the Hospital Anxiety and 
Depression Scale (HADS). This self-administered scale simultaneously 
evaluates anxiety (HADS-A) and depression (HADS-D). It consists of 
14 items (7 for the assessment of anxiety and 7 for the assessment of 
depression) scoring from 0 (no problem) to 3 (extreme problem). The 
cutoff values proposed by the HADS developers [25] were applied in 
order to determine the proportion of patients considered as unimpaired 
(not depressed, scoring ≤ 7 on each subscale), possibly impaired (8–10 
on each subscale), or probably impaired (≥ 11 on each subscale). In the 
present study Cronbach’s alpha was 0.69 for anxiety and 0.79 for the 
depression subscale.
Disease severity
The Uniﬁ  ed Parkinson’s Disease Rating Scale is a four-subscale combined 
instrument for assessing mental state, activities of daily living, motor 
examination and complications. Two further instruments are used 
together with the UPDRS, namely: (1) a modiﬁ  ed Hoehn & Yahr Staging, 
and (2) the Schwab & England Scale. Scores are obtained by interview and 
examination. It is currently used as a standard reference scale in clinical 
practice and research [18-20]. For our research we used the UPDR-III 
section.
Quality of life
Quality of life was assessed using the Parkinson’s Disease Quality of 
Life Questionnaire (PDQ-39) as the primary outcome measure [26]. It 
comprises 39 questions, each of them using a ﬁ  ve-point ordinal scoring 
system ranging from 0 (never had this problem) to 4 (always have this 
problem), from which a single summary index can be calculated. For the 
summary index the scores were standardized from 0 to 100, so that higher 
scores indicate more problems. PDQ-39 has been shown to be feasible, 
reliable, valid, and responsive to change in patients with PD and to have 38 CHAPTER  2
good internal consistency [27]; in our sample Cronbach’s alpha was 0.94. 
Basic sociodemographic data (age, gender) and disease duration 
were obtained from a structured interview. 
Statistical analysis
Discrete variables were compared using the χ2 – test. Continuous variables 
were compared with the Student t-test. Multiple linear regression analysis 
was performed to provide the coefﬁ   cients for examining the relative 
strength of the effects of PSQI, age, gender and disease duration, UPDRS, 
HADS-D and HADS-A on Quality of Life – the variables were entered 
in this order into the analysis using the enter method. The same method 
was then used with the ESS in place of the PSQI. As a ﬁ  nal step, multiple 
linear regression analysis was performed with the PSQI and the ESS 
together, using the enter method. These analyses were performed using 
the statistical software program SPSS 14.0 for Windows. 
Results
Descriptive Data
Of the 218 PD patients who met the inclusion criteria, 14 did not wish to 
participate in the study and 91 did not respond to the invitation. Patients 
were selected based on the database records of outpatient neurologists. 
The total response rate was 43.0%. Out of those who agreed to participate, 
7 patients were eliminated because of the exclusion criteria, 13 patients 
were not included because of missing data (these patients agreed to 
participate in the study, ﬁ  lled in the questionnaire, but refused to come 
for the oral interview), and 93 remained for analysis. Non-responders did 
not differ signiﬁ  cantly from the analyzed group in age (mean difference 
1.6 yrs., SE=1.22; t=1.315; 95%CI -0.798 – 4.003) or gender (difference 
between proportions 0.095, SE = 0.066, 95% CI -0.0343–0.224) (difference 
of proportions test) [28]. 
Ninety-three patients (46 men, 49.5%) completed the questionnaire. 
The mean age of the patients was 68.0±9.5 years. Mean disease duration 
was 6.1±5.9 years. Details of the clinical proﬁ  le and the study variables of 
the patients are shown in Table 1 and Table 2. 39
Table 1. Demographic and clinical description of the sample (n=93) 
Variable N (%), Mean±SD
1.  Gender Male 46 (49.5%)
Female 47 (50.5%)
2. Age 68.0±9.5
3. Disease duration 6.1±5.9
4. UPDRS total 35.3±20.4
UPDRS III 15.6±10.7
UPDRS IV 3.1±3.0
5. H Y 2.0±1.2
≤ 2.0 65 (69.9%)
6. S E 69.6±22.1
≤ 70% 41 (44.0%)
7. Antiparkinsonian drugs used
L-dopa 10 (10.7%)
Dopamine agonists 21 (22.6%)
L-dopa + COMT inhibitors 12 (12.9%)
L-dopa + Dopamine agonists 8 (8.6%)
L-dopa + COMT inhibitor + Dopamine agonists 6 (6.5%)
Other 36  (38.7%)
UPDRS - Unified Parkinson’s Disease Rating Scale. S E - Schwab   England Scale. H Y - 
Hoehn   Yahr Staging.40 CHAPTER  2
Table 2. Clinical description of the sample (n=93)
Variable Mean±SD, n, %
1. HADS-D 6.12±3.1
≥ 11  9 (9.7%) 
2. HADS-A 7.6±3.6
≥ 11 28 (30.1%) 
3. PSQI 9.1±4.9
≥ 5  68 (73.1%)
4. ESS 7.76±4.9
> 10 22 (23.7%)
5.  PDQ-39 – Summary Index 38.3±19.9
HADS – Hospital Anxiety and Depression Scale. PSQI – Pittsburgh Sleep Quality Index. ESS – Epworth 
Sleepiness Scale. PDQ-39 – Parkinson’s Disease Quality of Life Questionnaire.
Bivariate correlations between QoL and study variables
Table 3 presents the correlations between sociodemographic variables, 
disease severity, mood disorders, daytime and nighttime sleep disturbances 
and the quality of life summary index. The PDQ-39 Summary Index 
correlated signiﬁ  cantly with higher UPDRS-III (p<.01), increased levels 
of HADS-A and HADS-D (both p<.01), a higher PSQI score (p<.01) and 
higher ESS scores (p<.01). Sleep problems correlated positively with both 
HADS-D (p<.05) and HADS-A (p<.01), but only PSQI showed a signiﬁ  cant 
correlation with higher UPDRS scores (p<.05). No signiﬁ  cant correlations 
were found between ESS and UPDRS-III. 
Table 3. Bivariate correlations between QoL and sociodemographic and clinical variables
Age Gender Disease
duration UPDRS HADS-D HADS-A PSQI ESS
Gender -.04
Disease duration .10 -.03
UPDRS-III .13 -.10 .24*
HADS-D .09 .14 .19 .38**
HADS-A -.19 .14 .07 .35** .48**
PSQI -.03 .09 .15 .30* .28* .38**
ESS .12 -.01 .16 .23 .28* .36* .08
PDQ-39 SI .10 .01 .29* .76** .57** .60** .46** .27*
Displayed are Pearson’s coefficients. 
UPDRS – Unified Parkinson`s Disease Rating Scale, total score. HADS – Hospital Anxiety and Depression 
Scale (HADS-D for depression, HADS-A subscale for anxiety). PSQI – Pittsburgh Sleep Quality Index. 
ESS – Epworth Sleepiness Scale. PDQ-39 SI – Parkinson’s Disease Quality of life Questionnaire Summary 
Index41
Multiple regression analysis. Associations of QoL and study variables
A series of linear regression analyses was performed in order to evaluate 
the inﬂ  uence of sleep problems and mood disorders on quality of life; 
they are summarized in Tables 4 and 5. The variables were entered in 
hierarchical order into a linear regression model using the enter method 
in order to evaluate the changes in explained variance in PDQ-39. Table 
4 shows the analysis for PSQI and ESS separately, and Table 5 shows the 
analysis for PSQI and ESS together. 
PSQI explained 28-29% of the variance, with a signiﬁ  cant ΔR2 change 
(beta .21, p=.004), while ESS did not contribute to PDQ-39 (beta .04, p 
=.582, ΔR2 .09 was not signiﬁ  cant). UPDRS was signiﬁ  cant in all the models 
(beta .60-.64, p=.000). Anxiety was another variable that signiﬁ  cantly 
explained 6-13% of the variance (betas .32-.44, p=.000). Depression was 
not a signiﬁ  cant predictor of QoL in our sample (betas .11-.09). The model 
with PSQI explained 82%, the model with ESS 76%, and the overall model 
explained 82% of the variance. 42 CHAPTER  2
Table 4. Multiple linear regression analysis: Associations of sleep disorders, disease severity and mood 
disorders with quality of life, separately for quality of sleep and for excessive daytime somnolence 
(controlled for age, gender and disease duration)
Variables PDQ-39 Summary Index
beta p ΔR2 Adjusted R2
1. 1PSQI .20 .004 .28 *** .27
2. Age -.02 .757
Gender .13 .035
Disease duration .02 .797 .04 .27
3. UPDRS-III .60 .000 .42 *** .72
4. HADS-D .11 .133 .04 ** .76
5. HADS-A .32 .000 .06 *** .82
Adjusted R2 .82
Variables PDQ-39 Summary Index
beta p ΔR2 Adjusted R2
1. ESS -.02 .758 .08 * .07
2. Age .04 .561
Gender .10 .154
Disease duration .02 .738 .04 .05
3. UPDRS-III .64 .000 .49 ** .57
4. HADS-D .09 .243 .06 ** .62
5. HADS-A .44 .000 .13 *** .76
Adjusted R2 .76
Linear regression model. Variables entered in a hierarchical way in 5 blocks – 1. PSQI or ESS, 2. age, 
gender and disease duration, 3. UPDRS total score, 4. depression and 5. anxiety. PSQI – Pittsburgh 
Sleep Quality Index, ESS – Epworth Sleepiness Score, UPDRS-III – Unified Parkinson’s Disease Rating 
Scale, the part III, HADS-D – Hospital Anxiety and Depression Scale, depression subscale, HADS-A – 
Hospital Anxiety and Depression Scale, anxiety subscale. *p<.05, **p<.01, ***p<.001, represents the 
significance of R2 change.43
Table 5. Multiple linear regression analysis: Associations of sleep disorders, disease severity and mood 
disorders with quality of life (controlled for age, gender and disease duration)
Variables PDQ-39 Summary Index
beta p ΔR2 Sig. F Change Adjusted R2
1. ESS .04 .582 .09 .026 .07
2. PSQI .21 .004 .29 .000 .36
3. Age -.03 .669
Gender .13 .038
Disease duration .01 .929 .02 .682 .34
4. UPDRS-III .59 .000 .35 .000 .72
5. HADS-D .11 .127 .04 .006 .76
6. HADS-A .31 .000 .05 .000
Adjusted R2 .82
Linear regression model. Variables entered in a hierarchical way in 6 blocks – 1. ESS, 2. PSQI, 3. age, 
gender and disease duration, 4. UPDRS total score, 5. depression and 6. anxiety. ESS – Epworth 
Sleepiness Score, PSQI – Pittsburgh Sleep Quality Index, UPDRS-III – Unified Parkinson’s Disease Rating 
Scale, part III, HADS-D – Hospital Anxiety and Depression Scale, depression subscale, HADS-A – Hospital 
Anxiety and Depression Scale, anxiety subscale.
Discussion
Sleep disorders 
Our results show that sleep problems play an important role in the lives 
of the PD patients. Of our patients, 73.1% were poor sleepers during 
the nighttime. Adler et al. reported the occurrence of nocturnal sleep 
disturbances in 60-98% of PD patients [2], whereas in a more recent study, 
Martinez-Martin et al. in an their study reported insomnia in 45.7% of 
patients [29], using the Nonmotor Symptoms Questionnaire. Excessive 
daytime sleepiness was reported in 23.7% of our sample. Martinez-Martin 
reported sleepiness in 31.1% of PD patients [29]; Gjerstad et al. reported 
EDS in approximately 15% of PD patients, with an 8-year prevalence of 
54% [30].
Sleep disorders correlated signiﬁ  cantly with depression and anxiety, 
with the observed associations stronger for anxiety than for depression. 
Buysse et al. in their longitudinal study of insomnia and depression in 
young adults showed a strong relationship between these two problems 
[31]. Our research in PD patients shows signiﬁ  cant correlations of sleep 
disturbances and mood disorders. These results are partly similar to the 
observations of Borek et al., who in a sample of 185 PD patients found 44 CHAPTER  2
depression to have a signiﬁ  cant association with worse PSQI scores. In 
their study, the use of sleep medication also appeared to be a signiﬁ  cant 
predictor of worse PSQI scores, though anxiety and disease duration were 
not. Anxiety was also a signiﬁ  cant predictor of worse ESS scores, together 
with male gender and longer disease duration, but depression and the 
use of dopamine agonists were not [3]. Additionally, poor nocturnal sleep 
showed a relationship with worse UPDRS scores.
Sleep disorders and QoL
Quality of life showed signiﬁ   cant correlations with poor quality of 
nighttime sleep as well as with excessive daytime sleepiness. Different 
results were obtained when analyzing separately for the model with PSQI 
and for the model with ESS. PSQI appeared to be a signiﬁ  cant predictor of 
QoL, but ESS was not. A study by McKinlay et al. with 49 patients did not 
report sleep disturbances inﬂ  uencing QoL, but only one item of UPDRS 
was used for measuring sleep [32]. A study by Weintraub et al. showed 
ESS as having no signiﬁ  cant relationship with disability (measured by 
UPDRS-ADL score) in a sample of 114 PD patients [33]. Nocturnal sleep 
disturbances measured with the Parkinson’s Disease Sleep Scale correlated 
with worse QoL in a study of 77 PD patients by Scaravilli [10].
Mood disorders and QoL
Mood disorders are currently recognized as important nonmotor features 
of PD, and depression especially is thought to worsen QoL in PD patients 
[33]. The prevalence of depression in our sample is less common compared 
to previous studies [32,33], while the prevalence of anxiety is consistent 
with other studies [29,31]. However, our results show only anxiety as 
being a signiﬁ  cant factor associated with QoL, in both the model with 
PSQI and the model with ESS. Depression was not signiﬁ  cant in either 
model. Earlier published studies did not include anxiety in their analyses 
[33]; only recent studies increasingly show the importance of anxiety for 
QoL. A study by McKinlay et al. [32] in a sample of 49 PD patients and 
a study by Carod-Artal [13] in 115 PD patients both report depression as 
well as anxiety as being important factors related to QoL. A recent review 
of the HADS-A and HADS-D concluded that although these instruments 
may be useful in Parkinson’s disease for screening PD patients, they 
are not useful for adequately deﬁ  ning the severity of depression in this 
population [34].
Sociodemographic and clinical variables and QoL
Female gender was found to be a factor related to QoL in the model 
with PSQI. This result is similar to the ﬁ  nding of Behari et al, who also 
reported female gender as worsening QoL [15]. Karlsen et al. found a 
signiﬁ  cant relationship of higher age with the worse physical mobility 45
domain of QoL [14], while a study by Weintraiub et al. did not report such 
a relationship [33]. Chapuis et al. found longer disease duration to be a 
signiﬁ  cant predictor of worse QoL domains [8]. 
Disease severity was another factor signiﬁ  cantly inﬂ  uencing QoL in 
both models. Previously published papers have shown conﬂ  icting results. 
The studies by Chapuis et al. and Gomez-Esteban et al. reported worse 
functional status as being related with worse QoL [8,35], while Karlsen 
did not ﬁ  nd such a relationship [6].
Limitations
The relatively low response rate is the main limitation of our study. 
Patients were recruited mostly from outpatient neurologists, not from a 
specialized center for PD care, and only those who agreed to participate 
were included. For this reason, only patients who were able to come for 
the examination and interview – either alone or with a family member as 
a companion – formed our sample, so we assume that non-respondents 
were patients with worse disease severity, mostly bedridden. Despite the 
response rate, even this sample reported a high prevalence of sleep and 
mood problems, worsening quality of life, so we expect these factors to be 
even worse in the total PD patients group.
Clinical Implications 
Sleep problems, anxiety and depression must all be assessed in every PD 
patient and managed properly. The treatment of disturbed nocturnal sleep 
should include recommendations for sleep hygiene – the maintenance of 
a regular sleep-wake cycle, bed-time sleep restriction, the avoidance of 
frequent naps during the day, moderate day-time physical exercise and 
exposure to bright light in the daytime, especially towards evening in 
order to counteract any tendency towards anticipation of the sleep phase. 
Conclusions
Although sleep problems are not fully understood in their etiology 
(psychosocial determinants, treatment, neurodegeneration may play 
a role) [36], they are now regarded as important among the nonmotor 
symptoms of PD, closely associated, together with mood disorders, with 
worse QoL. Our study documents the importance of poor sleep at night 
and stresses not only the recognition of depression, but also the signiﬁ  cant 
importance of anxiety within the factors having an impact on QoL. By 
inﬂ  uencing potentially treatable conditions, clinicians could improve the 
QoL of PD patients.46 CHAPTER  2
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Abstract
Fatigue is frequent and important in the lives of Parkinson’s disease 
(PD) patients. It is multidimensional, with physical and mental aspects. 
The aim of our study was to explore the impact of fatigue on quality 
of life for PD patients. The sample consisted of 175 PD patients from 
Eastern Slovakia (52% males, mean age 68.2±9.2, mean disease duration 
7.4±6.7). The Multidimensional Fatigue Inventory (5 dimensions), the 
Parkinson’s Disease Quality of Life Questionnaire (8 dimensions) and the 
Uniﬁ  ed Parkinson’s Disease Rating Scale were used. Demographic data 
were obtained in a structured interview. T-test, Fisher`s exact test and 
multiple linear regression analysis were used. Different aspects of fatigue 
selectively explained different domains of QoL – physical dimensions 
of fatigue were connected with Mobility and Activities of daily living; 
mental fatigue dimensions affected Cognition, Emotional well-being, 
Communication and Activities of daily living; general fatigue was related 
to Bodily discomfort. The explained variances varied from 5% (Social 
Support) to 65% (Activities of daily living). Fatigue combined with worse 
functional status appears to be a signiﬁ  cant contributor to poor quality of 
life. Its multidimensional construct can be used to develop strategies for 
improving speciﬁ  c aspects of fatigue to improve QoL for PD patients.
Introduction
The cardinal motor features in Parkinson’s Disease (PD) have an 
important impact on the patients’ quality of life (QoL). However, PD is 
often complicated by additional problems such as depression, anxiety or 
fatigue, which may have even greater impact on their QoL [1].
Patients with PD have worse QoL scores compared to the general 
population, whether measured by a generic or by a disease-speciﬁ  c 
instrument. Karlsen et al. reported, using the Nottingham Health Proﬁ  le, 
worse scores in emotional reactions, energy, pain, sleep, social isolation 
and physical mobility domains [2]. Schrag et al. found worse scores in the 
domains of physical and social functioning, physical role limitations and 
general health perceptions, particularly in the younger age group [3]. When 
using the Parkinson’s Disease Questionnaire (PDQ-39), a disease-speciﬁ  c 
instrument, Schrag et al. reported deterioration of aspects of QoL related 
to physical and social functioning [3]. Various clinical and psycho-social 
variables have been evaluated with regard to QoL. Disease severity [4], 
motor complications [5,6], sleep problems [7], pain [8], depression [4,9], 
cognitive impairment [9] have been found to signiﬁ  cantly worsen QoL. 
Karlsen et al. found a signiﬁ  cant relationship between higher ageand the 
physical mobility domain [1], while other studies did not report such a 
relationship [2, 9]. Longer disease duration was a signiﬁ  cant predictor of 
the QoL domains [5]. Female gender was associated with worse QoL [10].51
Only recently fatigue has been recognized as an important clinical 
feature of PD, reported by 45% of patients [11,12]. To our knowledge 
only the study by Herlofson and Larsen was performed to evaluate the 
inﬂ  uence of fatigue on quality of life in PD patients [13]. They found a 
strong correlation between higher fatigue and worse QoL. Fatigue is a 
subjective experience, deﬁ  ned as a state of extreme tiredness, weakness, 
lack of energy or exhaustion, physical, mental, or both [14]. Recent studies 
report that the physical and mental components of fatigue seem to be 
independent from each other [15,16]. Physical fatigue in PD patients is 
reported after inadequate sleep or rest, or after physical exertion, and 
may be associated with decline in strength or in speed of movements due 
to parkinsonism. Mental fatigue is reported after mental effort or when 
patients lack the motivation to initiate activities [16].
The aim of our study was to explore the impact of the various 
dimensions of fatigue controlled for age, gender, disease duration, level 
of education and functional status on the quality of life of PD patients. 
Methods
Patients
This cross-sectional study evaluated fatigue in patients with Parkinson’s 
disease recruited from the hospitals and outpatients departments in the 
East Slovakian region between February 2004 and November 2005. All 
patients were diagnosed according to the United Kingdom Parkinson’s 
Disease Society Brain Clinical Criteria [17], and their mental abilities were 
assessed with the Mini- Mental State Examination (MMSE) [18]. Exclusion 
criteria were deﬁ  ned as follows: 1. MMSE lower than 24; 2. disease duration 
longer than 15 years, to avoid a sample of very old people, who might be 
expected to have serious co-morbidities that could affect QoL; 3. presence 
of co-morbidity associated with the fatigue variable.
The study was approved by the local Ethical Committee. Informed 
consent was obtained from each patient. 
Data collection 
Data were collected by means of a mailed questionnaire comprising 
questions on socio-demographic background, medical history and 
current medication, as well as self-report questionnaires including the 
Multidimensional Fatigue Inventory (MFI) and Parkinson’s Disease 
Quality of Life Questionnaire (PDQ-39). After three weeks all patients 
were interviewed on relevant issues that were no part of the questionnaire. 
After this structured interview, a neurologist assessed each patient’s 
disease severity with the Uniﬁ   ed Parkinson’s Disease Rating Scale 52 CHAPTER  3
(UPDRS) Version 3.0 [19], including Hoehn and Yahr staging [20] and the 
Schwab and England disability scale [21]. Patients who were not able to 
ﬁ  ll in the questionnaires by themselves because of motor impairment of 
their hands answered the questions during an oral interview.
Measures
Quality of life was assessed with a disease-speciﬁ  c questionnaire, the 
Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), as the primary 
outcome measure. It was designed by Peto et al. [22], and comprises 
39 questions, each of them using a ﬁ  ve-point ordinal scoring system 
ranging from 0 (never had this problem) to 4 (always have this problem), 
from which eight subdimension scores and one summary index can be 
calculated: Mobility – 10 items; Activities of daily living (ADL) – 6 items; 
Emotional well-being – 6 items; Stigma – 4 items; Social support – 3 items; 
Cognition – 4 items; Communication – 3 items; and Bodily discomfort – 3 
items. For each QoL dimension the scores were standardized from 0 to 
100, so that higher scores refer to more problems. PDQ-39 has been shown 
to be feasible, reliable, valid, and responsive to change in patients with PD 
with good internal consistency [23]; in our sample Cronbach’s alpha was 
0.94. Cronbach’s alpha for each of the subscales was: Mobility 0.87, ADL 
0.90, Emotion Well-Being 0.86, Stigma 0.88, Social Support 0.78, Cognition 
0.67, Communication 0.76, Bodily Discomfort 0.81.
Fatigue was assessed with the Multidimensional Fatigue Inventory 
(MFI). The MFI is a 20-item self-report instrument designed and validated 
by Smets et al. [24]. It measures ﬁ  ve fatigue domains: general fatigue, 
physical fatigue, mental fatigue, reduced motivation, and reduced activity. 
There are four items in each domain. The score on each item ranges from 1 
(no fatigue) to 5 (very fatigued), so the score in each dimension ranges from 
4 (no fatigue) to 20 (highest possible fatigue). This instrument is frequently 
used among patients with neurological diseases [16]. The instrument was 
found to have good internal consistency with Cronbach’s alpha coefﬁ  cient 
of 0.89 in our sample. Cronbach’s alpha for the subscales were as follows: 
general fatigue 0.84, physical fatigue 0.79, reduced activity 0.80, reduced 
motivation 0.71, mental fatigue 0.82.
The Uniﬁ   ed Parkinson’s Disease Rating Scale is a four-subscale 
combined scale (mental state, activities of daily living, motor examination, 
and complications). Two further instruments are attached to the UPDRS, 
namely: (1) a modiﬁ  ed Hoehn & Yahr Staging, an ordinal scale that is 
applied to gauge the course of disease over time; and (2) the Schwab & 
England Scale, a measure of functional independence providing scores 
that, though expressed as percentages, form an ordinal scale. Scores are 
obtained by interview and examination. It is currently used as a standard 53
reference scale in clinical practice and research [19-21].
Basic socio-demographic data (age, gender, education) were 
obtained from a structured interview. The level of education was classiﬁ  ed 
into three categories: 1. basic – for primary education or for secondary 
education without school leaving examination, 2. middle – secondary 
education with school leaving examination and 3. higher – college or 
university degrees. 
Statistical analysis
The relationships between demographic variables, functional status, 
fatigue and quality of life were analyzed with multiple linear regression 
analysis, using all separate quality of life domains as dependent variables. 
Independent variables considered for the multivariate model were the ﬁ  ve 
fatigue dimensions, controlled for age, gender, level of education, disease 
duration and UPDRS total scores. A stepwise method was used, with the 
variables entered in 2 blocks – the ﬁ  rst block containing the variables that 
were controlled for, then a second block was added containing the fatigue 
domains. Only variables with signiﬁ   cant correlations were entered. 
Statistical analyses were performed using the statistical software program 
SPSS 12.0 for Windows.
Results
Descriptive Data
Out of 497 patients with PD meeting the inclusion criteria, 41 did not 
wish to participate in the study; and 259 did not respond to the invitation. 
Total response rate was 35.2%. Out of those who agreed to participate, 11 
patients were eliminated because of the exclusion criteria, 11 patients were 
not included because of missing data (these patients agreed to participate 
in the study, ﬁ  lled in the questionnaire, but refused to come for the oral 
interview), and 175 remained for analysis. Non-responders did not differ 
signiﬁ  cantly from the analyzed group in age (mean age of responders: 
68.2±9.2 years, non responders 71.8±8.1 years, t test sig .280, CI -0.91 – 
.069). Responders differed signiﬁ  cantly in gender (P=0.023, two-sided, 
Fisher`s exact test). Table 1.
175 patients completed the questionnaire and were interviewed, 
followed by examination by the neurologist (91 men, 52%). The mean age 
of the patients was 68.2±9.2 years. Mean age at disease onset was 59.5±11.1 
years. Mean disease duration was 7.4±6.7 years. Details of the clinical 
proﬁ  le and variables of the patients are shown in Table 1 and Table 2. 54 CHAPTER  3
Table 1 Socio-demogrpahic variables of the sample (N=175) and non-resoders (N=322)
Responders Non responders
Variable n, %, Mean±SD Variable n, %, Mean±SD 
1. Gender
Male (n=91) 52.0% Male (n=132) 41.0%
Female (n=84) 48.0% Female (n=190) 59.0%
2 Age 68.2±9.2 71.8±8.1
3. Disease duration 7.4±6.7
4. Level of education
Basic 91 (52.0%)
Middle 58 (33.1%)
Higher 26 (14.9%)
Table 2 Clinical variables of the sample (N=175)
Mean±SD
UPRDS 36.2±21.2
H Y 2.2±1.1 
≤ 2.0 110 (62.9%)
> 2.0 65 (37.1%)
S E 70.0±21.2
≤ 70% 76 (43.4%)
> 70% 99 (56.6%)
MFI
General fatigue 13.6±4.0
Physical fatigue 13.9±3.6
Reduced activity 12.5±3.9
Reduced motivation 10.8±3.8
Mental fatigue 11.8±3.7
PDQ-39
Mobility 63.4±24.8
Activities of daily living 58.7±25.6
Emotional well-being 62.5±20.6
Stigma 53.0±25.7
Social support 40.8±19.8
Cognition 59.0±19.6
Communication 50.8±21.6
Bodily discomfort 74.4±23.3
Summary index 57.7±15.6
UPDRS Unified Parkinson’s Disease Rating Scale, total score; H Y Hoehn and Yahr staging; S E 
Schwab and England disability scale. MFI Multidimensional Fatigue Inventory, PDQ-39 Parkinson’s 
Disease Quality of Life Questionnaire.55
Correlations 
Table 3 presents the correlations between sociodemographic variables 
and PDQ-39 and functional status and PDQ-39. Higher age signiﬁ  cantly 
correlated with worse Mobility, Activities of daily living, Cognition 
(p<.01) and Communication (p<.05); female gender showed signiﬁ  cant 
correlation only with Bodily discomfort (p<.05). Longer disease duration 
had signiﬁ  cant correlations with all QoL domains. Lower level of education 
correlated with Mobility, Activities of daily living, Emotional well-being 
and Bodily discomfort. Worse UPDRS had signiﬁ  cant correlations with 
all QoL domains. 
All QoL domains (except Social support) positively correlated with 
all fatigue dimensions (p<.01). The Social support domain signiﬁ  cantly 
correlated only with general fatigue, reduced motivation and mental 
fatigue (p<.05). 
We did an analysis of possible multicollinearity of the fatigue subscales; its 
results gave us additional information on the independence of the physical 
and mental components of fatigue.
Multiple regression analysis of PDQ-39 scores 
Only variables with signiﬁ  cant correlation to QoL domains were entered 
into the multiple linear regression model. Table 4 shows that mental 
fatigue and higher UPDRS scores were the two determinants related to 
overall quality of life.
Mobility was predicted by reduced activity and higher UPDRS. 
This model explained 56% of the variance. Activities of daily living was 
predicted by reduced activity and by higher UPDRS. This model explained 
65% of the variance. Emotional well-being was affected by general fatigue 
and mental fatigue, by longer disease duration and higher UPDRS score. 
The model explained 27% of the variance. The Stigma domain was 
associated with reduced activity, reduced motivation, and worse disease 
severity. This model explained 12% of the variance. Social support was 
related to reduced motivation, with 5% of the explained variance. Higher 
score in Cognition was predicted by mental fatigue and higher age. The 
model explained 40% of the variance. Communication was predicted by 
mental fatigue and by higher UPDRS. The model explained 20% of the 
variance. Bodily discomfort was predicted by general fatigue, by higher 
UPDRS and female gender. The model explained 21% of the variance. 56 CHAPTER  3
T
a
b
l
e
 
3
 
F
a
t
i
g
u
e
 
a
s
 
p
r
e
d
i
c
t
o
r
 
o
f
 
q
u
a
l
i
t
y
 
o
f
 
l
i
f
e
 
f
o
r
 
e
a
c
h
 
o
f
 
t
h
e
 
e
i
g
h
t
 
d
o
m
a
i
n
s
 
o
f
 
P
D
Q
-
3
9
;
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
 
a
g
e
,
 
g
e
n
d
e
r
,
 
l
e
v
e
l
 
o
f
 
e
d
u
c
a
t
i
o
n
,
 
d
i
s
e
a
s
e
 
d
u
r
a
t
i
o
n
 
a
n
d
 
f
u
n
c
t
i
o
n
a
l
 
s
t
a
t
u
s
P
D
Q
-
3
9
M
o
b
i
l
i
t
y
A
D
L
E
m
o
t
i
o
n
a
l
W
e
l
l
-
b
e
i
n
g
S
t
i
g
m
a
S
o
c
i
a
l
s
u
p
p
o
r
t
C
o
g
n
i
t
i
o
n
C
o
m
m
u
n
i
c
a
t
i
o
n
B
o
d
i
l
y
d
i
s
c
o
m
f
o
r
t
S
u
m
m
a
r
y
I
n
d
e
x
A
g
e
.
0
3
-
.
0
5
N
E
N
E
N
E
.
2
6
*
*
*
.
1
4
N
E
N
E
G
e
n
d
e
r
N
E
N
E
N
E
N
E
N
E
N
E
N
E
.
2
5
*
*
N
E
E
d
u
c
a
t
i
o
n
-
.
0
2
-
.
0
3
.
1
2
N
E
N
E
N
E
N
E
-
.
0
9
-
.
0
6
D
i
s
e
a
s
e
 
d
u
r
a
t
i
o
n
-
.
0
2
.
0
7
.
1
7
*
.
1
2
.
0
6
.
1
0
.
0
5
.
0
4
.
1
2
U
P
D
R
S
.
5
0
*
*
*
.
7
5
*
*
*
.
2
5
*
*
.
2
8
*
*
-
.
0
2
.
1
3
.
3
7
*
*
*
.
2
7
*
*
.
4
6
*
*
*
A
d
j
u
s
t
e
d
 
R
2
#
.
4
8
.
6
4
.
2
0
.
0
6
.
0
1
.
2
4
.
1
8
.
1
8
.
4
3
M
F
I
G
e
n
e
r
a
l
 
f
a
t
i
g
u
e
-
.
0
1
-
.
0
1
.
3
4
*
*
.
1
1
.
0
9
.
0
5
-
.
0
6
.
2
9
*
.
1
4
P
h
y
s
i
c
a
l
 
f
a
t
i
g
u
e
-
.
0
3
.
0
3
-
.
1
1
.
0
5
N
E
.
0
2
-
.
0
9
-
.
1
5
-
.
0
4
R
e
d
u
c
e
d
 
a
c
t
i
v
i
t
y
.
3
4
*
*
*
.
2
8
*
-
.
1
4
.
2
4
*
N
E
-
.
0
2
-
.
0
6
.
1
2
-
.
0
6
R
e
d
u
c
e
d
 
m
o
t
i
v
a
t
i
o
n
.
0
1
.
0
6
.
0
3
.
3
3
*
*
.
2
7
*
.
0
1
.
1
2
-
.
1
0
.
1
2
M
e
n
t
a
l
 
f
a
t
i
g
u
e
.
0
2
.
1
0
.
2
5
*
.
1
5
.
0
2
.
4
6
*
*
*
.
2
6
*
-
.
0
1
.
3
2
*
*
*
A
d
j
u
s
t
e
d
 
R
2
.
5
6
.
6
5
.
2
7
.
1
2
.
0
5
.
4
0
.
2
0
.
2
1
.
4
8
L
i
n
e
a
r
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
i
s
 
e
n
t
e
r
e
d
 
i
n
 
2
 
b
l
o
c
k
s
 
–
 
t
h
e
 
f
i
r
s
t
 
b
l
o
c
k
 
c
o
n
t
a
i
n
s
 
v
a
r
i
a
b
l
e
s
 
t
h
a
t
 
a
r
e
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
,
 
t
h
e
 
s
e
c
o
n
d
 
b
l
o
c
k
 
c
o
n
t
a
i
n
s
 
t
h
e
 
f
a
t
i
g
u
e
 
d
o
m
a
i
n
s
,
 
o
n
l
y
 
t
h
e
 
v
a
r
i
a
b
l
e
s
 
w
i
t
h
 
s
i
g
n
i
f
i
c
a
n
t
 
c
o
r
r
e
l
a
t
i
o
n
s
 
w
e
r
e
 
e
n
t
e
r
e
d
,
 
a
 
s
t
e
p
w
i
s
e
 
m
e
t
h
o
d
 
w
a
s
 
u
s
e
d
,
 
o
n
l
y
 
s
i
g
n
i
f
i
c
a
n
t
 
c
o
n
t
r
i
b
u
t
o
r
s
 
r
e
m
a
i
n
e
d
 
i
n
 
t
h
e
 
m
o
d
e
l
.
 
D
i
s
p
l
a
y
e
d
 
r
e
s
u
l
t
s
 
a
r
e
 
b
e
t
a
s
,
 
r
e
p
r
e
s
e
n
t
i
n
g
 
t
h
e
 
a
n
a
l
y
s
i
s
 
o
f
 
a
l
l
 
t
h
e
 
v
a
r
i
a
b
l
e
s
.
P
D
Q
-
3
9
 
P
a
r
k
i
n
s
o
n
’
s
 
D
i
s
e
a
s
e
 
Q
u
a
l
i
t
y
 
o
f
 
L
i
f
e
 
Q
u
e
s
t
i
o
n
n
a
i
r
e
 
,
 
U
P
D
R
S
 
U
n
i
f
i
e
d
 
P
a
r
k
i
n
s
o
n
’
s
 
D
i
s
e
a
s
e
 
R
a
t
i
n
g
 
S
c
a
l
e
.
 
N
E
 
n
o
t
 
e
n
t
e
r
e
d
.
 
#
 
A
d
j
u
s
t
e
d
 
R
2
 
f
o
r
 
t
h
e
 
l
i
n
e
a
r
 
r
e
g
r
e
s
s
i
o
n
 
a
n
a
l
y
s
i
s
 
o
f
 
v
a
r
i
a
b
l
e
s
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
.
 
 
A
d
j
u
s
t
e
d
 
R
2
 
o
f
 
a
l
l
 
v
a
r
i
a
b
l
e
s
.
 
D
i
s
p
l
a
y
e
d
 
a
r
e
 
b
e
t
a
 
c
o
e
f
f
i
c
i
e
n
t
s
.
 
*
p
 
≤
 
0
.
0
5
;
 
*
*
p
 
≤
 
0
.
0
1
;
 
*
*
*
p
 
≤
 
0
.
0
0
157
Discussion
Research involving populations with chronic neurological disease has 
shown fatigue to be associated with lower levels of QoL [25,26]. Until now, 
little research has been performed into the association between fatigue 
and QoL for PD patients
The presence of fatigue in PD patients predicts worsening of all 
QoL domains. The most affected were the domains Bodily Discomfort, 
Mobility and Emotional well-being. Focusing on the different components 
of fatigue, mental domains (especially mental fatigue) were predictors 
of psychological QoL domains (Emotional well-being, Stigma, Social 
support, Cognition, Communication). Physical dimensions of fatigue 
(reduced activity) were predictors of Mobility, ADL and Stigma domains. 
Fatigue in general appeared to be a predictor of the Emotional well-being 
and Bodily Discomfort domains. 
Fatigue is often reported as one of the major complaints in PD patients. 
Its impact on their QoL is not fully understood [13,27,28]. In a community-
based study of 245 PD patients compared to 100 healthy individuals and 
100 patients with diabetes mellitus, Larsen et al. found more fatigue and 
poorer QoL among PD patients than in healthy individuals or in diabetes 
patients [27]. In a more recent study, Herlofson and Larsen compared 66 
PD patients with and without fatigue. They reported fatigued patients as 
having signiﬁ  cantly worse QoL in Emotional well-being and Mobility. No 
difference was observed in Cognition, Communication and Stigma [29]. 
Our results show in addition that mental fatigue signiﬁ  cantly inﬂ  uences 
the Emotional well-being, Cognition and Communication domains.
Other factors also had a signiﬁ  cant  inﬂ   uence on QoL. Disease 
severity measured by UPDRS was a signiﬁ  cant predictor for all domains 
except Social support and Cognition. The inﬂ  uence of functional status 
on QoL had conﬂ  icting results in previous studies. In a community-based 
sample of 111 patients Karlsen et al. did not ﬁ  nd that motor complications 
signiﬁ  cantly  inﬂ   uenced QoL scores measured with the Nottingham 
Health Proﬁ  le [2]. In contrast, Chapuis et al. using a disease-speciﬁ  c 
questionnaireon on a sample of 143 PD patients, found worse motor scores 
were connected with worse scores for Mobility and ADL [5].
In our study the inﬂ   uence of fatigue on QoL was controlled for 
demographic variables, as their inﬂ  uence was conﬁ  rmed by previous 
studies. We found higher age  to be a signiﬁ   cant predictor of worse 
Cognition. Karlsen et al. found a signiﬁ  cant relationship of higher age 
with the physical mobility domain of the NHP questionnaire [1], but other 
studies did not report the inﬂ  uence of age on QoL [2,9]. Female gender was 
found to have a signiﬁ  cant inﬂ  uence on the Bodily Discomfort domain in 
our study. Chapuis et al. found male gender signiﬁ  cantly worsened the 58 CHAPTER  3
ADL [5]. Behari et al. found female gender had the most inﬂ  uence on QoL 
[10]. Longer disease duration was a signiﬁ  cant predictor of the Emotional 
well-being domain. Chapuis et al. showed an inﬂ  uence of longer disease 
duration on worse scores for Mobility, Activities of daily living, Stigma, 
Social Support and Communication [5]. 
For the purposes of measuring fatigue we decided to use a generic 
measure, as its advantage is the possibility of using a generic instrument 
for different patient groups and consequently, to compare them. Fatigue 
is a frequent complaint of PD patients. The developers of the MFI did not 
propose cut-off scores, but statistical rules allow the possibility of using 
the upper 2/3 of the scores as a cut-off. In our sample 49.5% of patients 
complained of general fatigue, 53.7% of physical fatigue, 37.7% of reduced 
activity, 39.0% of reduced motivation and 37.2% of mental fatigue. These 
ﬁ  gures are consistent with the studies reporting the frequency of fatigue 
in 40-56% of PD patients [12]. 
There were limitations in our research. Our sample consisted mostly 
of patients who were able to come for the examination and interview – either 
alone or with a family member as a companion, so we suppose that non-
responders were patients with worse functional status, mostly bedridden. 
Differences in gender between responders and nonn responders showed 
men to more likely to participate in our study, meaning that our sample 
is not fully representative, though gender proved not to be a signiﬁ  cant 
variable affecting QoL except Bodily discomfort. Despite the rather low 
response rate, fatigue is already a serious problem worsening patients’ 
quality of life, so we expect this to be even worse in the total PD patients 
group. The present study was not controlled for depression and sleep 
disorders, as there is an overlap in symptomatology – sleep problems and 
fatigue are among the diagnostic criteria for depression and vice versa. 
Future studies are to be performed to understand their contribution to 
QoL as well. 
To our knowledge this is the ﬁ  rst study separately evaluating different 
fatigue domains and their inﬂ  uence on quality of life. The strength of 
our study is the use of a disease-speciﬁ  c instrument, as it better reﬂ  ects 
the consequences of the disease for individuals, and is more sensitive 
compared to generic instruments that contain more general items and 
therefore lack speciﬁ  city.
While clinicians are mostly concerned with physical manifestations, 
the affected persons tend to identify other problems also related to their 
quality of life. We stress the importance of recognizing different aspects of 
fatigue in PD patients because of their negative effect on different quality of 
life domains. Improvement of physical fatigue by proper antiparkinsonian 
drug therapy may improve Mobility and ADL, and improvement of mental 
fatigue by psychological interventions or patient education may improve 
Emotional well-being, ADL or Cognition domains. The frequency, severity 59
and impact of fatigue on QoL suggest that new research should be done in 
this area. Identifying a more effective approach to managing this problem 
should be one of the current challenges in PD treatment. 
Conclusion
Fatigue is frequent and important in the lives of PD patients. It is 
multidimensional, with physical and mental aspects, having signiﬁ  cant 
negative effects on all QoL domains, especially Bodily Discomfort, Mobility 
and Emotional well-being. It is important to identify it its presence, and 
its proper management to improve quality of life for PD patients.
Acknowledgements
This work was supported by the Slovak Research and Development 
Agency under Contract  No. APVV-20-038305.
References
(1)   Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Inﬂ  uence of clinical 
and demographic variables on quality of life in patients with Parkin-
son’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 1999; 
66:431-435.
(2)   Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality 
of life in Parkinson’s disease: a prospective longitudinal study. Jour-
nal of Neurology, Neurosurgery, and Psychiatry 2000; 69:584-589.
(3) Schrag  A,  Jahanshahi M, Quinn N. How does Parkinson’s disease af-
fect quality of life? A comparison with quality of life in the general 
population. Movement Disorders 2000; 15:1112-1118.
(4)  The Global Parkinson`s Disease Survey (GPDS) Steering Committee. 
Factors impacting on quality of life in Parkinson’s disease: results 
from an international survey. Movement Disorders 2002; 17:60-67.
(5)   Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the 
motor complications of Parkinson’s disease on the quality of life. 
Movement Disorders 2005; 20:224-230.
(6)  Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Par-
kinson’s disease on quality of life and health-related costs: a prospec-
tive European study. European Journal of Neurology 2005; 12:956-963.
(7) Scaravilli  T,  Gasparoli E, Rinaldi F, Polesello G, Bracco F. Health-re-
lated quality of life and sleep disorders in Parkinson’s disease. Neuro-
logical Sciences 2003; 24:209-210.
(8)  Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson’s 
disease: a controlled cross-sectional study. Parkinsonism & Related 
Disorders 2004; 10:129-136.
(9) Schrag  A,  Jahanshahi M, Quinn N. What contributes to quality of life 60 CHAPTER  3
in patients with Parkinson’s disease? Journal of Neurology, Neurosur-
gery, and Psychiatry 2000; 69:308-312.
(10)  Behari M, Srivastava AK, Pandey RM. Quality of life in patients with 
Parkinson’s disease. Parkinsonism & Related Disorders 2005; 11:221-
226.
(11)  van Hilten JJ, Weggeman M, van der Velde EA, Kerkhof GA, van Dijk 
JG, Roos RA. Sleep, excessive daytime sleepiness and fatigue in Par-
kinson’s disease. Journal of Neural Transmission. Parkinson’s Disease and 
Dementia Section 1993; 5:235-244.
(12) Karlsen K, Larsen JP, Tandberg E, Jorgensen K. Fatigue in patients 
with Parkinson’s disease. Movement Disorders 1999; 14:237-241.
(13) Herlofson K, Larsen JP. Measuring fatigue in patients with Parkin-
son’s disease - the Fatigue Severity Scale. European Journal of Neurol-
ogy 2002; 9:595-600.
(14)  Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue 
scale. Parkinsonism & Related Disorders 2005; 11:49-55.
(15) Zenzola A, Masi G, De Mari M, Defazio G, Livrea P, Lamberti P. Fa-
tigue in Parkinson’s disease. Neurological Sciences 2003; 24:225-226.
(16)  Lou JS, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fa-
tigue and mental fatigue in Parkinson’s disease. Movement Disorders 
2001; 16:190-196.
(17) Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diag-
nosis of idiopathic Parkinson’s disease: a clinico-pathological study 
of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry 1992; 
55:181-184.
(18)  Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practi-
cal method for grading the cognitive state of patients for the clinician. 
Journal of Psychiatric Research 1975; 12,189-198. 
(19) Fahn S, Elton RL, members of the UPDRS Development Committee. 
Uniﬁ  ed Parkinson’s disease rating scale. In: Fahn S, Marsden CD, 
Calne DB, Lieberman A, editors. Recent developments in Parkinson’s 
disease, vol. 2. Florham Park, NJ: MacMillan Healthcare Information, 
1987: 153–163.
(20) Hoehn MM, Yahr MD. Parkinsonism onset progression and mortal-
ity. Neurology 1967; 17:427-442.
(21)  Schwab RS, England AC. Projection technique for evaluating surgery 
in Parkinson’s disease. In: Gillingham FJ, Donaldson IMI, editors. 
Third symposium on surgery in Parkinson’s disease. Edinburg: Liv-
ingstone, 1969: 152-157.
(22) Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and 
validation of a short measure of functioning and well being for indi-
viduals with Parkinson’s disease. Quality of Life Research 1995; 4:241-
248.61
(23) Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related 
quality of life in Parkinson’s disease: a systematic review of disease 
speciﬁ  c instruments. Journal of Neurology, Neurosurgery, and Psychiatry 
2002; 72:241-248.
(24) Smets EMA, Grassen B, Bonke B, De Haes JCJM. The multidimen-
sional fatigue inventory (MFI) psychometric qualities of an instru-
ment to assess fatigue. Journal of Psychosomatic Research 1995; 39:315-
325.
(25) Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are as-
sociated with poor quality of life in ALS. Neurology 2003; 60:122-123.
(26) Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Qual-
ity of life in multiple sclerosis: the impact of depression, fatigue and 
disability. Multiple Sclerosis 2001; 7:340-344.
(27) Larsen JP, Karlsen K, Tandberg E. Clinical problems in non-ﬂ  uctu-
ating patients with Parkinson’s disease: a community-based study. 
Movement Disorders 2000; 15:826-829.
(28) Martinez-Martin P, Catalan MJ, Benito-Leon J, et al. Impact of fatigue 
in Parkinson’s disease: the Fatigue Impact Scale for Daily Use (D-
FIS). Quality of Life Research 2006; 15:597-606.
(29) Herlofson K, Larsen JP. The inﬂ  uence of fatigue on health-related 
quality of life in patients with Parkinson’s disease. Acta Neurologica 
Scandinavica 2003; 107:1-6.62 CHAPTER  463
Chapter 4
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Abstract
Objectives
Many patients with Parkinson’s disease (PD) suffer from non-motor 
symptoms like sleep disturbances, excessive daytime sleepiness and 
fatigue. The aim of our research was to explore whether fatigue is related 
to sleepiness and sleep problems, depression and functional status, 
controlled for age, gender and disease duration.
Methods
The sample consisted of 78 PD patients from Eastern Slovakia (52% males, 
mean age 68.8±8.7, mean disease duration 7.2±6.8). The Multidimensional 
Fatigue Inventory (5 dimensions), the Epworth Sleepiness Scale, the 
Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale 
and the Uniﬁ  ed Parkinson’s Disease Rating Scale were used. Demographic 
data were obtained in a structured interview. Multiple linear regression 
was used to analyse the data.
Results   
Sleepiness did not show signiﬁ  cant association with fatigue in any of the 
fatigue domains; neither did quality of sleep. Depression was signiﬁ  cantly 
associated with all domains of fatigue, the strongest being the relationship 
with general fatigue (  .42), reduced motivation (  .39), mental fatigue (  
.35) (p<.001), and physical fatigue (  .31) (p<.01), while the relationship 
with reduced activity was less strong (  .22) (p<.05). Worse functional 
status was signiﬁ  cantly related to reduced activity (  .50), general fatigue 
(  .35), physical fatigue (  .35), and mental fatigue (  .35) (p<.001). 
Conclusion
Fatigue is not related to daytime sleepiness or nighttime sleep dysfunction. 
Fatigue is more strongly inﬂ   uenced by the presence of depression 
and worse functional status. 
Introduction
Fatigue is a common symptom in the general population as well as in 
people with chronic disorders. Approximately 10% of visits to primary 
care providers is for assessment of fatigue [1-5]. In Parkinson’s disease (PD) 
patients the prevalence of fatigue ranges from 33% to 58% [6]. One third of 
PD patients consider fatigue their single most disabling symptom [1,5].
Fatigue is a complex phenomenon involving a number of psychosocial 
and behavioural processes. The concept of fatigue, as a multidimensional 
phenomenon in Parkinson’s disease patients, was postulated by Lou et al. 
[7]. It is characterized by difﬁ  culty in initiating and sustaining mental and 
physical tasks in the absence of motor or physical impairment [1,7,8]. The 
study by Lou et al. demonstrated that the severity of physical fatigue does 
not correlate with that of mental fatigue, suggesting that the two are to 
a certain extent independent [7].65
It may be difﬁ  cult to separate fatigue and sleepiness from each other. 
These two terms are often used interchangeably, or under the general 
rubric of being ‘tired’, despite the distinct diagnostic or therapeutic 
implications that each of them has [9], leading to suboptimal interventions 
or management strategies in response to patients’ complaints.
Sleepiness is a ubiquitous phenomenon, experienced not only as a 
symptom in a number of medical, psychiatric and primary sleep disorders, 
but also as a normal physiological state by most individuals over any given 
24 hour period [9]. Sleepiness can be considered abnormal when it occurs 
at inappropriate times, or does not occur when desired. Excessive day-
time sleepiness (EDS) was reported in approximately 15% of PD patients, 
with an 8-year prevalence of 54% [10]. Its manifestation may be either 
rapid – ‘sleep attacks’, or slow – patients may feel sleepy and slowly drift 
off to sleep [11]. If unrecognized and untreated, sleepiness can result in 
poor attention and memory and even to accidents. The study by Gjerstad 
et al. showed that EDS was related to higher age, male gender and use of 
dopamine agonists [10]. Recent studies performed in chronic neurological 
diseases and primary sleep disorders have shown that the level of fatigue 
does not correlate with the levels of day-time sleepiness, suggesting that 
fatigue and EDS are not causally related to each other [12,13].
As many as 98% of patients with PD may suffer at some time from 
nocturnal symptoms that can disturb their sleep [11]. These symptoms 
may be grouped into four broad categories; insomnia, motor, urinary 
and neuropsychiatry problems. PD patients show reduced total sleep 
time and sleep efﬁ  ciency, and an increased number of sleep arousals and 
fragmentations of sleep [11]. About 40% of PD patients take sedatives, 
signiﬁ  cantly more than are taken by elderly people without PD. Sleep 
disturbance correlates with disease severity, and depression is another 
factor strongly related with sleep problems [14]. 
To our knowledge, the relationship between fatigue and sleep 
problems has not been studied in a group of PD patients, and little is 
known even about patients with other chronic diseases. The study by 
Kaynak was performed with multiple sclerosis (MS) patients [15]; 27 MS 
patients reporting fatigue were compared with 10 MS patients without 
fatigue and with 13 participants in the control group. Fatigued patients 
were found to have worse sleepiness and worse quality of their sleep, 
thus the conclusion was that fatigue could be partially explained by poor 
subjective sleep quality. 
Fatigue in PD still remains an imperfectly understood problem, and 
it seems to have been recognized as serious only recently. While more is 
known about its prevalence and impact on patients’ lives, little progress 
has been made so far in understanding its aetiology and pathogenesis. 
Biological [16], clinical and psychosocial variables may all play a role 
[17,18].66 CHAPTER  4
A study by Shulman reported fatigue as being associated with 
anxiety and activities of daily life, but not with gender, age or depression, 
or with motor dysfunction [17]. A study by Abe et al. also did not ﬁ  nd any 
correlation of fatigue with motor dysfunction [16]. In a longitudinal study 
by Alves et al., fatigue was related to disease severity, depression, and 
excessive daytime somnolence (EDS) [18,19].
The aim of our research was to explore whether fatigue is related 
to sleepiness and sleep problems, depression and functional status, 
controlled for age, gender and disease duration.
Methods
Patients
This cross-sectional study evaluated fatigue in a study population of 
78 patients with Parkinson’s disease. The patients were recruited from 
the hospitals and outpatients departments in the East Slovakian region 
between February 2004 and November 2005. All patients were diagnosed 
according to the United Kingdom Parkinson’s Disease Society Brain 
Clinical Criteria [20] and their mental abilities were assessed with the 
Mini- Mental State Examination (MMSE) [21]. Patients with idiopathic 
Parkinson’s disease were also included. Exclusion criteria were deﬁ  ned as 
follows: 1. MMSE lower than 24; 2. disease duration longer than 15 years; 
3. presence of co-morbidity associated with the fatigue variable.
The study was approved by the local Ethics Committee. Informed 
consent was obtained from each patient. 
Data collection 
Data were collected by means of a mailed questionnaire comprising 
questions on socio-demographic background, medical history and 
current medication, as well as self-report questionnaires including the 
Multidimensional Fatigue Inventory (MFI), Epworth Sleepiness Scale 
(ESS), Pittsburgh Sleep Quality Index (PSQI) and Hospital Anxiety and 
Depression Scale (HADS). After three weeks all patients were interviewed 
on relevant issues that were not part of the questionnaire. After this 
structured interview, a neurologist assessed each patient’s disease severity 
with Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) Version 3.0 [22], 
including Hoehn and Yahr staging [23] and the Schwab and England 
disability scale [24]. Patients who were not able to ﬁ  ll in the questionnaires 
by themselves because of motor impairment of their hands answered the 
questions during an oral interview.67
Measures
Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI). 
The MFI is a 20-item self-report instrument designed and validated by 
Smets et al. [25]. It measures ﬁ  ve fatigue domains: general fatigue, physical 
fatigue, mental fatigue, reduced motivation, and reduced activity. There 
are four items in each domain. The score on each item ranges from 1 (no 
fatigue) to 5 (very fatigued), so the score in each dimension ranges from 4 
(no fatigue) to 20 (highest possible fatigue). This instrument is frequently 
used for patients with neurological diseases [7]. The instrument was found 
to have good internal consistency with a Cronbach’s alpha coefﬁ  cient of 
0.89 in our sample. Cronbach’s alpha results for the subscales were as 
follows: general fatigue 0.84, physical fatigue 0.79, reduced activity 0.80, 
reduced motivation 0.71, mental fatigue 0.82.
For the evaluation of day-time somnolence the Epworth Sleepiness 
Scale (ESS) [26] was used. ESS relies on measuring dozing behaviour in 
eight different situations. The questionnaire asks the respondent to rate 
the likelihood of falling asleep on a scale from 0 to 3, were 0 indicates 
no chance and 3 represents the greatest chance of dozing. The total ESS 
score is the sum of all the responses and ranges from 0 to 24, with higher 
scores reﬂ  ecting greater sleep propensity. Consistent with the reports of 
a number of previous investigations, a score of 10 as the cut-off point was 
used for normal, while scores above this imply pathological sleepiness 
[27]. Hagell et al. demonstrated good psychometric properties of the 
ESS in PD patients, giving the evidence basis for using it in PD [28]. The 
instrument was found to have good internal consistency with a Cronbach’s 
alpha coefﬁ  cient of 0.84 in our sample.
The Pittsburgh Sleep Quality Index (PSQI) [29] was used to assess 
night-time sleeping problems. PSQI assesses global sleep quality and 
disturbances in sleep patterns during the previous month in seven 
components: subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efﬁ  ciency, sleep disturbances, use of sleep medication and 
daytime dysfunction. Scoring of answers ranges from 0 (no difﬁ  culty) to 
3 (severe difﬁ  culty). After recoding, each component has possible scores 
0 – 3, where 3 indicates the negative extreme. The global PSQI score is 
the sum of all the component scores (range 0 – 21); a score of 5 or more 
indicating a poor sleeper. Although not validated for PD, this instrument 
is widely used in PD studies [30-32]. The instrument was found to have 
good internal consistency with a Cronbach’s alpha coefﬁ  cient of 0.81 in 
our sample. 68 CHAPTER  4
Depression was assessed using the Hospital Anxiety and 
Depression Scale (HADS). This self-administered scale simultaneously 
evaluates anxiety (HADS-A) and depression (HADS-D). It was designed 
to identify mood disorders in non-psychiatric outpatients attending 
hospital consulting rooms. It consists of 14 items (7 for the assessment 
of anxiety and 7 for the assessment of depression) scoring from 0 (no 
problem) to 3 (extreme problem). The cut-off values as proposed by the 
HADS developers [33] were applied in order to determine the proportion 
of patients considered as unimpaired (not depressed, scoring ≤ 7 on each 
subscale), possibly impaired (8–10 on each subscale), or probably impaired 
(≥ 11 on each subscale). In the present study Cronbach’s alpha was 0.79 for 
the depression domain.
The Uniﬁ   ed Parkinson’s Disease Rating Scale is a four-subscale 
combined scale - mental state, activities of daily living, motor examination, 
and complications. Two further instruments are attached to the UPDRS, 
namely: (1) a modiﬁ  ed Hoehn & Yahr Staging, an ordinal scale that is 
applied to gauge the course of disease over time; and (2) the Schwab   
England Scale, a measure of functional independence providing scores 
that, though expressed as percentages, form an ordinal scale. Scores are 
obtained by interview and examination. It is currently used as a standard 
reference scale in clinical practice and research [22-24].
Basic socio-demographic data (age, gender) and disease duration 
were obtained from the structured interview. 
Statistical analysis
The relationships linking age and gender with disease duration, functional 
status, depression and sleepiness or sleep quality were analyzed with 
multiple linear regression analysis, using all separate fatigue domains 
as dependent variables. Statistical analyses were performed using the 
statistical software program SPSS 12.0 for Windows.
Results
Out of 203 patients with PD meeting the inclusion criteria, 14 did not 
wish to participate in the study; and 91 did not respond to the invitation. 
Total response rate was 38.4%. Out of those who agreed to participate, 
7 patients were eliminated because of the exclusion criteria, 13 patients 
were not included because of missing data (these patients agreed to 
participate in the study, ﬁ  lled in the questionnaire, but refused to come 
for the oral interview), and 78 remained for analysis. Non-responders did 
not differ signiﬁ  cantly from the analyzed group in age (mean difference 69
1.6 yrs., SE=1.22; t=1.315; 95%CI -0.798 – 4.003) or gender (difference 
between proportions 0.095, SE = 0.066, 95% CI -0.0343–0.224) (difference 
of proportions test) [34]. 
Having completed the questionnaire, the 78 patients were 
interviewed, and then subsequently examined by the neurologist (41 
men, 52.6%). The mean age of the patients was 68.8±8.7 years. Mean age 
at disease onset was 59.5±11.1 years. Mean disease duration was 7.2±6.8 
years. Details of the clinical proﬁ  le and the study variables of the patients 
are shown in Table 1 and Table 2. 
Table 1. Demographic and clinical description of the sample (n=78) 
Variable n, %, Mean±SD
1. Gender 
Male (n=41) 52.6%
Female (n=37) 47.4%
2. Age 68.8 ± 8.7
3. Disease duration 7.2 ± 6.8
4. UPDRS* 35.9 ± 20.3
5. H Y* 2.0 ± 1.1
≤ 2.0 55 (71.4%)
> 2.0  23 (28.6%)
6. S E* 70.4 ± 21.2
≤ 70% 33 (42.3%)
> 70% 45 (57.7%)
7. Antiparkinsonian drugs used
L-dopa 8 (10.3%)
Dopamine agonists 21 (26.8%)
L-dopa + COMT inhibitors 12 (15.4%)
L-dopa + Dopamine agonists 6 (7.7%)
L-dopa + COMT inhibitor + Dopamine agonists 6 (7.7%)
Other 25  (32.1%)
UPDRS - Unified Parkinson’s Disease Rating Scale. S E - Schwab   England Scale. H Y - 
Hoehn   Yahr Staging.70 CHAPTER  4
Table 2. Description of the study variables in the sample (n=78)
Variable n, %, Mean±SD
1. HADS-D 6.61 ± 3.9
≥ 11 11 (14.3%)
2. ESS 7.74 ± 4.9
> 10 20 (25.6%)
3. PSQI 10.8 ± 5.6
≥ 5  65 (83.3%)
4. MFI
General fatigue 13.8 ± 4.0 
Physical fatigue 13.7 ± 3.3
Reduced activity 12.5 ± 3.8
Reduced motivation 10.7 ± 3.8
Mental fatigue 11.8 ± 3.5
HADS – Anxiety and Depression Scale. ESS – Epworth Sleepiness Scale. PSQI – Pittsburgh Sleep Quality 
Index. MFI – Multidimensional Fatigue Inventory
The Spearman’s correlation of ESS and PDQI showed no signiﬁ  cant 
relations (Spearman’s coefﬁ  cient.048). 
As sleepiness may be one of the major symptoms reﬂ  ecting sleep 
disturbances, two models of multiple linear regression analysis were 
performed to explore the relative contributions of functional status, 
depression and sleepiness (Table 3), or subjective quality of sleep (Table 
4), in each MFI domain, controlled for age, gender and disease duration.71
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The Uniﬁ  ed Parkinson’s Disease Rating Scale had signiﬁ  cant effects on all 
domains of fatigue except reduced motivation in both models. Depression 
had a signiﬁ  cant effect on all fatigue domains in both models, the strongest 
being on reduced motivation in both models (beta 0.50 in the sleepiness 
model, and 0.48 in the quality of sleep model). 
Sleepiness did not contribute signiﬁ  cantly to fatigue in any of the 
fatigue domains (betas ranged from 0.05 to 0.16). When all variables were 
added into the model, the R2 change for sleepiness ranged from 0.01 in 
general fatigue, reduced activity and mental fatigue to 0.02 in physical 
fatigue and reduced motivation in the model. 
Similar results were found in the quality of sleep model. Quality 
of sleep was not a signiﬁ  cant variable contributing to fatigue in any of 
the fatigue domains (betas ranged from 0.10 to 0.20), its R2 change scores 
ranging from 0.01 in general fatigue and reduced motivation, 0.02 in 
mental fatigue and reduced activity to 0.04 in mental fatigue. 
None of the variables which the analysis was controlled for, whether 
age or gender or disease duration, proved to be signiﬁ  cant for any of the 
ﬁ  ve fatigue outcomes in either of the models. 
 
The proposed model for sleepiness explained 36% of the variance in 
general fatigue, 31% of the variance in physical fatigue, 37% in reduced 
activity, 28% in reduced motivation and 29% in mental fatigue. The 
proposed model for quality of sleep explained 36% of the variance in 
general fatigue, 31% of the variance in physical fatigue, 38% in reduced 
activity, 28% in reduced motivation and 32% in mental fatigue. 
Discussion
The aim of our study was to evaluate whether fatigue is related to sleepiness 
and nocturnal sleep problems, depression and functional status, controlled 
for age, gender and disease duration. Neither sleepiness during the day, 
nor nocturnal sleep problems (quality of sleep) contributed to fatigue in 
any of the ﬁ  ve fatigue domains. Depression contributed signiﬁ  cantly to all 
ﬁ  ve fatigue domains, and functional status to four domains.
Looking closer at fatigue, sleepiness and sleep disturbances, clear 
associations are difﬁ  cult to deﬁ  ne as overlaps among them exist. Many 
patients reporting fatigue have day-time sleepiness or night-time sleep 
complaints [15], and many sleep-disordered patients have psychological 
complaints [13]. The terms are also often used interchangeably, grouped 
together by patients under the complaint of being ‘tired’. On closer 
examination, however, it can be seen that sleepiness, sleep disturbances 
and fatigue are distinct, but interrelated symptoms.
ESS has been described in 8-50% of PD patients [17], and in our 
sample it was observed in 25.6% of the patients. When put into the linear 73
regression model, sleepiness did not have a signiﬁ  cant relationship with 
fatigue in any of the ﬁ  ve fatigue domains. This contrasts with the study 
by Alves et al. [19], who found in a sample of 233 PD patients that fatigue 
was associated with excessive daytime sleepiness, although when the 
patients with excessive daytime sleepiness were excluded, the prevalence 
of fatigue was still high, indicating the possibility that fatigue may result 
from sleepiness, but not necessarily so. The relative independence of 
fatigue and sleepiness was also reported for the multiple sclerosis patients 
in the study by Kaynak et al. [15], although these two populations are 
difﬁ  cult to compare as MS and PD affect different age groups. 
Sleep problems are well-known and well-described non-motor 
symptoms in PD. They may result from uncontrolled motor complications, 
medication side-effects, or as a result of degeneration of the neuro-
anatomical substrate responsible for the sleep-wake cycle [11]. As many 
as 60% of PD patients suffer from sleep disturbances, and up to 98% may 
suffer at some time from nocturnal symptoms that can disturb their sleep 
[11]. In our sample, 83.3% of patients reported poor sleep. When analyzing 
quality of sleep in the proposed fatigue models, poor sleep quality did not 
have a signiﬁ  cant relationship to fatigue in any of the ﬁ  ve fatigue domains. 
Only Karlsen et al., studying a sample of 233 PD patients, evaluated the 
association of fatigue and sleep problems, which they measured in terms 
of the use of sedatives; they found that the incidence of fatigue correlated 
with the use of sleeping pills [35]. 
Mood disorders
Depression is common among PD patients [17]. In our study it was reported 
by 14.3% of patients. Depression proved to be an important contributor to 
fatigue in all the fatigue domains; the greater the depression, the greater 
the fatigue. These results contrast with those of Shulman et al. [17], who 
in their sample of 99 PD patients did not ﬁ  nd fatigue correlating with 
depression, using the Fatigue Severity Scale and the Beck Depression 
Inventory. Similar results to Shulman were published by Abe in a sample 
of 26 PD patients [16], using the Fatigue Severity Scale and Zung’s self-
assessed depression scale. Looking at the multidimensional construct of 
fatigue, Lou et al. with a sample of 39 PD patients found that depression 
was associated with the mental dimension of fatigue, but not with the 
physical dimensions [7]. The relationship between fatigue and depression 
is still controversial as there may be an overlap between them; fatigue is 
among the diagnostic criteria for depression.
Functional status
We found that functional status had a signiﬁ  cant inﬂ  uence on fatigue for 
the domains of general fatigue, physical fatigue and mental fatigue, the 
strongest being with the domain of reduced activity. These ﬁ  ndings do 74 CHAPTER  4
not correspond with previous results. In their study of 233 PD patients, 
Karlsen et al. [35] found that disease severity did not have signiﬁ  cant 
associations with fatigue, measured with the Nottingham health proﬁ  le 
questionnaire, in its dimension “lack of energy”; and Lou et al. [7] also 
found no signiﬁ   cant correlations of disease severity measured with 
Hoehn&Yahr with any of the dimensions in the MFI. 
Limitations
Our sample consisted mostly of patients who were able to come for the 
interview, so we assume that the non-responders were patients with 
worse functional status compared to those in our sample. Nonetheless, 
our study suggests that even in this selected population of PD patients, 
fatigue is already a serious problem.
As fatigue was shown to be a complex construct, with the physical and 
mental components independent from each other [7], the Multidimensional 
Fatigue Inventory was selected for measuring fatigue. This instrument as 
a generic measure also gives the possibility of comparisons with other 
diseases, in contrast to the disease-speciﬁ  c Parkinson’s Fatigue Scale [36], 
or the Fatigue Severity Scale, which measures fatigue per se [37]. 
Implications
In our study we discovered that all the fatigue domains, mental as well 
as physical, are strongly related to depression and worse functional 
status, but are independent from subjective sleep disorders or sleepiness. 
As symptoms of fatigue and sleep dysfunction overlap, further research 
should be performed, cross-sectional as well as longitudinal, to better 
understand these associations. The explanation of this issue is important 
as it may inﬂ  uence the future clinical management of PD patients. We also 
stress the importance of identifying possible treatable disorders leading 
to fatigue. Recognition and proper treatment of depression, and proper 
management of the disease symptoms, may lead to improvement in both 
the mental and the physical dimensions of fatigue. 
Conclusions
Fatigue is not related to day-time sleepiness or night-time sleep 
dysfunction. Fatigue is more strongly inﬂ   uenced by the presence of 
depression and worse functional status. 
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Abstract
Fatigue is an important contributor to poor quality of life. The aim of our 
research was to identify factors associated with fatigue among patients 
with Parkinson’s disease (PD). The sample consisted of 150 patients. The 
Multidimensional Fatigue Inventory (MFI), Uniﬁ  ed Parkinson’s Disease 
Rating Scale (UPDRS), Hospital Anxiety and Depression Scale (HADS) 
and Charlson co-morbidity index were used for analysis. Demographic 
data were obtained in a structured interview. T-test,  2-test and general 
linear regression were used. Fatigue was reported in 81% of the patients, 
with the worst scores in physical fatigue. Mood disorders and worse 
UPDRS scores were associated with fatigue. 
Introduction
Fatigue is a frequent complaint of patients with Parkinson’s disease 
(PD) with up to 40-56% of patients reporting it during the course of 
their disease [01 - 04], of whom 15-33% describe it as the most disabling 
symptom [05]. Like other non-motor problems, fatigue is often an under-
appreciated and neglected symptom, despite the fact that it may even 
precede the appearance of cardinal motor signs [06]. Fatigue may be 
present as a transient or persistent feature of PD [07]. Fatigue is also an 
important contributor to poor quality of life in PD and it is connected to 
worse physical and mental health [08, 09]. 
Fatigue is a subjective experience. Although lacking a standard 
deﬁ   nition, fatigue can be deﬁ   ned as a state of extreme tiredness, 
weakness, lack of energy or exhaustion, physical, mental, or both [10]. 
Physical fatigue in PD patients is reported after inadequate sleep or rest, 
or after physical exertion, and may be associated with physical condition, 
or decline in strength generation or in speed of repetitive movements due 
to parkinsonism. Mental fatigue is reported after mental effort or when 
patients lack the motivation to initiate activities, and may result from 
sleep disturbances, slowed mental processes, or depression [11]. 
Fatigue has been described in various chronic diseases, neurological 
and non-neurological. It is reported to be the major problem in multiple 
sclerosis patients, 55-79% of them suffering from fatigue [12, 13] up to 42–
80% of patients with rheumatoid arthritis [14], and 57% of patients with 
primary Sjögren`s syndrome [15]. Several studies have been performed to 
identify correlates of fatigue in chronic disorders. Associations between 
fatigue, disease severity or disease activity have been found, as well as 
associations between fatigue and depression or sleep disorders, but not 
with age or disease duration [12, 13, 15].
In recent years fatigue has become an important research variable 81
and several studies have highlighted its clinical signiﬁ  cance in Parkinson’s 
disease. While more is known about its prevalence and impact on the 
lives of patients, little progress has been made so far in understanding 
its etiology and pathogenesis. Biological [16], clinical and psychosocial 
variables may play a role [07, 11]. As yet there are few ﬁ  ndings suggesting 
how to manage the problem clinically. One possible way is the recognition 
and proper management of factors leading to occurrence of fatigue. 
Parkinson’s disease is a disorder particularly affecting more elderly 
patients. This population suffers from a higher incidence of cardiovascular, 
neurovascular disorders, diseases of bones and joints [17, 18], and these 
conditions also require more frequent hospital admissions [18]. As these 
disorders are often associated with patients’ complaints of fatigue [14, 15, 
19], it is possible that the presence of these accompanying problems may 
lead to fatigue or may increase feelings of fatigue. As this disease mainly 
worsens patients’ functional status (through worsening of movement 
abilities or pain), we expect co-morbidities to inﬂ   uence the physical 
dimensions of fatigue. 
So far the variables predicting fatigue in Parkinson’s disease have 
not been clariﬁ  ed. The aim of this study is to identify some clinical and 
psychosocial factors associated with the occurrence of fatigue in PD 
patients.
Methods
Patients
This cross-sectional study evaluated fatigue in a study population of 
150 patients with Parkinson`s disease. The patients were recruited from 
the hospitals and outpatients departments in the East Slovakian region 
between February 2004 and November 2005, based on medical records. 
All patients were diagnosed according to the United Kingdom Parkinson’s 
Disease Society Brain Clinical Criteria [20] and their mental abilities were 
assessed with the Mini-Mental State Exam (MMSE) [21]. The sample 
included patients with idiopathic Parkinson’s disease. Exclusion criteria 
were deﬁ  ned as follows: 1. MMSE lower than 24; 2. disease duration longer 
than 15 years and 3. comorbidities associated with fatigue. 
The study was approved by the local Ethical Committee. Informed 
consent was obtained from each patient. 
Data collection 
All participating patients received a mailed questionnaire accompanied 
by a written informed consent form. After three weeks all patients were 82 CHAPTER  5
interviewed on relevant issues that were no part of the questionnaire. 
After this structured interview, a neurologist assessed the patient’s disease 
severity with the Uniﬁ   ed Parkinson’s Disease Rating Scale (UPDRS 
Version 3.0, [22]), including Hoehn and Yahr staging [23] and the Schwab 
and England disability scale [24]. Patients who were unable to ﬁ  ll in the 
questionnaire because of tremor, motor impairment of their hand or visual 
problems answered the questions during an oral interview.
Sample description
150 patients (77 men – 51.3%, 73 women – 48.7%) completed the 
questionnaire and the interview, followed by examination by the 
neurologist. The mean age of the patients was 68.4 ± 8.8 years (range 44 – 
83 years); 69.1 ± 8.6 of men and 67.7 ± 8.9 of women. Mean age at disease 
onset was 61.5 ± 11.1 years. Mean disease duration was 7.9 ± 7.9 years; 
7.09 ± 5.4 for the male population and 8.9 ± 9.8 for women. These gender 
differences were statistically not signiﬁ  cant. Details of the clinical proﬁ  le 
and variables of the patients are shown in Table 1.
Table 1 Clinical variables of Parkinson’s disease patients (N = 150). 
Variable  %, Mean ± SD
1. UPRDS* 36.9 ± 20.9 
Male (n = 77) 38.8 ± 21.1 
Female (n = 73) 34.9 ± 19.4
2. Anxiety 8.2 ± 3.9
≥ 11 46 (30.6%)
< 11 104 (69.4%)
3. Depression  6.7 ± 3.7
≥ 11 21 (14.0%)
< 11 129 (86.0%)
4. Charlson index 3.9 ± 1.8
5. Scores for MFI* domains General fatigue 13.8 ± 4.1
Physical fatigue 14.1 ± 3.6
Reduced activity 12.7 ± 3.8
  Reduced motivation 11.0 ± 3.8
Mental fatigue 11.9 ± 3.8
6. Antiparkinsonian drugs used L-dopa 18 (12%)
Dopamine agonists 36 (24%)
L-dopa + COMT inhibitors 38 (25.3%)
L-dopa + Dopamine agonists 20 (13.3%)
L-dopa + COMT inhibitor + Dopamine agonists 16 (10.7%)
Other 22  (14.7%)
*UPDRS - Unified Parkinson’s Disease Rating Scale, MFI - Multidimensional Fatigue Inventory83
Measures
Multidimensional Fatigue Inventory (MFI)
Fatigue was assessed with the Multidimensional Fatigue Inventory (MFI) 
as the primary outcome measure in PD patients. The MFI is a 20-item self-
report instrument designed and validated by Smets et al. [25]. It measures 
ﬁ   ve dimensions of fatigue: general fatigue, physical fatigue, mental 
fatigue, reduced motivation, and reduced activity. There are four items 
in each dimension. The score on each item ranges from 1 (no fatigue) to 5 
(very fatigued). The score in each dimension ranges from 4 (no fatigue) to 
20 (highest possible fatigue). This instrument is a frequently-used fatigue 
questionnaire in Europe, repeatedly used in patients with neurological 
diseases [11]. It has been successfully applied in several clinical groups. 
In the present research the instrument was found to have good internal 
consistency with Cronbach’s alpha coefﬁ  cient of 0.84. 
Hospital Anxiety and Depression Scale (HADS) 
Anxiety and depression were assessed using the Hospital Anxiety and 
Depression Scale (HADS). This self-administered scale simultaneously 
evaluates anxiety (HADS-A) and depression (HADS-D). It consists of 14 
items (7 for assessment of anxiety and 7 for assessment of depression) 
scoring from 0 (no problem) to 3 (extreme problem). The cut-off values 
were applied in order to determine the proportion of patients considered 
unimpaired (not anxious or not depressed, scoring ≤ 7 on each subscale), 
possibly impaired (8–10 on each subscale), or probably impaired (≥ 11 on 
each subscale) [26]. In the present study Cronbach’s alpha was 0.82 for the 
anxiety domain and 0.79 for the depression domain.
The Uniﬁ  ed Parkinson’s Disease Rating Scale
The Uniﬁ   ed Parkinson’s Disease Rating Scale is a four-subscale 
measure (mental state, activities of daily living, motor examination, and 
complications). Two further instruments are attached to the UPDRS, 
namely: (1) a modiﬁ  ed Hoehn & Yahr Staging; and (2) the Schwab & 
England Scale. Ratings are observation-based, and scores are obtained by 
interview and physical examination. As a consequence of its design, the 
UPDRS allows for partial and total scores. [22 – 24].
Comorbidities
The Charlson index was used to evaluate the presence of comorbidities. It 
consists of 19 conditions (some of them representing two degrees of severity 
of the same condition) with values of 1 - 6, based on the adjusted risk of 
one-year mortality. The overall comorbidity score reﬂ  ects the cumulative 
increased likelihood of one-year mortality. It has been combined with age 
to form an age–comorbidity index [27, 28]. Two independent researchers 84 CHAPTER  5
assessed comorbidities on the basis of patients’ questionnaires. Differences 
were resolved through discussion with reference to a third reviewer if 
necessary.
Personal characteristics
Age, gender, disease duration and educational level of the patient were 
based on the Neurology Department registry information and conﬁ  rmed 
at the time of interview. Gender (0 = male and 1 = female) and educational 
level were used in the regression analysis as covariates with the level of 
education coded as: 1. basic (primary education or for secondary education 
without school leaving examination, 2. middle (secondary education 
with school leaving examination) and 3. higher (college or university 
degrees). 
Statistical analysis
Discrete variables were compared with the  2 test and are presented as 
percentages. Continuous variables were compared with the Student t 
test and are presented as mean ± SD. P-values < 0.05 were considered 
statistically signiﬁ   cant. Based on the conceptual model, a series of 
regression were established to provide the coefﬁ  cients to examine the 
relative strength of disease duration, Charlson index, anxiety, depression 
and UPDRS, Hoehn and Yahr staging, and Schwab and England scores on 
ﬁ  ve domains of fatigue: general fatigue, physical fatigue, reduced activity, 
reduced motivation and mental fatigue.
The coefﬁ  cients provided are standardized regression coefﬁ  cients 
(beta) that identify the net effects (i.e. controlling for other covariates) 
of each variable on the respective outcome. The regression analysis also 
provides basic goodness-of-ﬁ   t information (R2 and p-values) for the 
respective equations.
Statistical analyses were performed using the statistical software 
program SPSS 12.0 for Windows.
Results
Out of 497 patients with PD meeting the inclusion criteria, 41 did not 
wish to participate in the study; and 284 did not respond to the invitation. 
Total response rate was 30.2%. Out of those who agreed to participate, 11 
patients were excluded because of the exclusion criteria, 11 patients were 
not included because of missing data (these patients agreed to participate 
in the study, ﬁ  lled in the questionnaire, but refused to come for the oral 
interview), and 150 remained for analysis. Non-responders did not differ 
signiﬁ  cantly from the analyzed group in age (mean difference, 1.9 yrs., 
SE=0.78; t=1.965; 95%CI 0.46 – 3.54). However, males were overrepresented 
in the study sample, difference 8.1%, SE = 0.049; 95% CI -0.015 – 17.6% 
(difference of proportions test) [29].85
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Looking ﬁ  rst at the disease-related factors, comorbidity and disease 
duration were not signiﬁ  cant for any of the ﬁ  ve fatigue outcomes. However, 
the Uniﬁ  ed Parkinson’s Disease Rating Scale had signiﬁ  cant effects on all 
domains of fatigue, as well as depression. Depression (beta = -0.55) had 
the strongest association with reduced motivation. Both depression and 
UPDRS were signiﬁ  cantly related to higher levels of reduced motivation 
(beta = 0.55), but anxiety was related to lower levels of motivation. 
Depression also had an important relation to general fatigue, 
physical fatigue, activity and mental fatigue (beta = 0.34, 0.31, 0.34 and 
0.29, respectively). Importantly, these relationships persisted when the 
effects of gender and educational level were statistically controlled.
The proposed models explained 34% of the variance in general 
fatigue, 36% of the variance in physical fatigue, 38% in activity, 35% in 
motivation and 34% in mental fatigue respectively.
Discussion
Fatigue is considered to be a part of normal aging [30], but the high 
prevalence of fatigue in PD patients cannot be explained only by the 
advanced age of these patients. Our study moreover shows fatigue as not 
being related to gender and age. This corresponds with the ﬁ  ndings of 
studies in other chronic disorders, where age as well as gender was not 
related to fatigue; in fact, these disorders affect much younger populations 
[11, 13, 31]. Similarly, the level of education proved not to be associated with 
fatigue. Existing studies on PD patients and other progressive disorders 
also failed to show signiﬁ  cant relationship between fatigue and disease 
duration [07, 12, 15]. 
Nearly 50% of PD patients report the presence of at least one co-
morbidity [18]. Based on the ﬁ  ndings of the high prevalence of fatigue in 
cerebrovascular diseases [19] and diseases of joints and bones [14, 15], we 
expected that these accompanying problems might affect patients’ levels 
of fatigue. Co-morbidities were reported by 47% of our sample, especially 
vascular events (35%) and joints diseases (12%). For all the ﬁ  ve domains, 
however, co-morbidities did not appear to be signiﬁ  cant. The explanation 
of this observed non-signiﬁ  cant relationship is not clear at this moment, 
and further studies should be performed in future. 
Depression was signiﬁ   cantly related to each of the ﬁ  ve  fatigue 
domains. It was identiﬁ  ed in 14% of our sample, which is less prevalent 
than was documented in previous studies [01, 32]. A higher level of 
depression is associated with a higher level of fatigue. This relationship 
was the strongest for reduced motivation and reduced activity, weaker for 
general and physical fatigue and the weakest for mental fatigue. These 
ﬁ  ndings are partly similar to the ﬁ  ndings of Lou et al. [11]; in a sample 
of 39 PD patients depression was related to mental dimensions of fatigue 87
(mental fatigue), but not with physical fatigue. The association between 
depression and fatigue is still controversial because of the possible overlap 
in symptomatology between PD and major depression: fatigue and sleep 
problems are among the diagnostic criteria for both. Leentjens et al., [33] 
in their study proposed the use of an adjusted cut-off score 18/19 for 
better discrimination between depressed and non-depressed PD patients; 
however, as the sample size was small relative to the number of items, this 
ﬁ  nding should be viewed with some caution. 
The term anxiety is used to denote an intermittent or sustained 
emotional state characterized by subjective  feelings of nervousness, 
irritability, uneasy anticipation and apprehension [34]. Anxiety signs 
usually accompany depression. Anxiety was reported in 30.6% of our 
sample. We found anxiety to be connected with reduced motivation and 
general fatigue. Although we found a correlation between anxiety and 
mental fatigue, in the multiple linear regression model anxiety did not 
prove to be associated with mental fatigue dimensions. Anxiety also has 
an overlap in symptomatology with fatigue, as has depression; increased 
muscular tension, giddiness, trembling and sweating are among the 
diagnostic criteria for anxiety disorder [34].
Patients scored higher in the physical fatigue domain. A possible 
explanation is that Parkinson’s disease affects more physical abilities 
(stiffness, slow movements, tremor), although non-motor problems 
(depression, anxiety, sleep difﬁ   culties, sensory symptoms) are also 
frequent and disabling [01]. 
We found functional status to have a signiﬁ  cant relationship with all 
ﬁ  ve fatigue domains, strongest for the physical fatigue and weakest for the 
reduced motivation domain. The physical component of fatigue appears 
to be associated with worse functional status as patients may have less 
muscle strength and less energy supply. Garber et al. [05] evaluated fatigue, 
physical activity and physical function in a non-random sample of 37 PD 
patients, and they found that patients with more severe fatigue had poorer 
physical function compared with patients with less fatigue. Our ﬁ  ndings 
on the relation between functional status and all the MFI components are in 
contrast with the study of Karlsen et al. [03], who found no relationship in a 
sample of 233 PD patients between disease severity measured by UPDRS and 
fatigue. However, in their study fatigue was measured not with a disease-
speciﬁ  c instrument, but with the Nottingham Health Proﬁ  le; fatigue was 
considered as a manifestation of the energy domain. The ﬁ  ndings of the 
study of Lou et al. [11] in a sample of 39 PD patients also do not correspond 
with our results. In their study disease severity measured by Hoehn&Yahr 
did not correlate with any of the dimensions in the MFI.
There were limitations to the present research. Our sample consisted 
mostly of patients who were able to come for the examination and 88 CHAPTER  5
interview – either alone or with a family member as a companion, so we 
suppose that non-responders were patients with worse functional status, 
mostly bedridden. Despite the rather low response rate, in this selected 
population fatigue is already a serious problem, so we expect this to be 
even worse in the total PD patients group.
This is the ﬁ  rst time, to our knowledge, that factors related to the 
separate components of fatigue have been studied. Previous studies 
showed an association of depression with the mental dimensions of fatigue, 
but we have discovered in our study that depression has an important 
relationship not only with the mental dimensions of fatigue, but with the 
physical dimensions as well. Further studies focusing on behavioural and 
psychosocial factors should be performed in future, cross-sectional as well 
as longitudinal, to better understand this problem and to explore the role 
of these factors leading to fatigue over time.
Neurologists frequently fail to recognize fatigue. General problems 
in assessing fatigue are its subjective nature, and in PD particularly the 
high prevalence of other non-motor symptoms that may overlap. The 
new onset of fatigue in an older individual may be connected to the 
development of a somatic or psychiatric disease. We suggest that the 
elevated levels of fatigue in PD patients deserve special attention, with the 
development of strategies to relieve this complaint. As PD is a progressive 
disorder, in clinical practice neurologists often challenge the worsening of 
functional status, even in cases of optimal treatment with antiparkinsonian 
drugs. This is why we stress the importance of identifying other possible 
treatable disorders leading to fatigue. Treatment of depression may lead 
to improvement in both mental and physical dimensions of fatigue. 
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Chapter 6
Fatigue in Parkinson’s disease is 
influenced by depression and worse 
functional status
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Abstract
Background
Fatigue is a frequent nonmotor complaint of patients with Parkinson’s 
disease (PD). Despite increasing knowledge on fatigue, the factors leading 
to its development are still not recognized. The aim of our study was to 
examine how disease severity explains the different fatigue domains, how 
disease severity explains depression, and how disease severity explains 
via depression the different fatigue domains.
Methods
The sample consisted of 190 PD patients (93 men, 48.9%, mean age 68.2±9.3 
years, mean disease duration 6.4±4.7 years), recruited form the hospitals 
and outpatients in East Slovakia region. The Multidimensional Fatigue 
Inventory, the Hospital Anxiety and Depression Scale and the Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) were used for the analysis. 
LISREL analysis was performed to evaluate the data.
Results
UPDRS increased the level of fatigue in General fatigue (ß=.35), Physical 
fatigue (ß=.82), Reduced activity (ß=.34) and Mental fatigue (ß=.29), but 
not Reduced motivation. UPDRS increased directly the level of depression 
(ß=.26), and via this pathway the levels of General fatigue (ß=.25), Reduced 
activity (ß=.31), Reduced motivation (ß=.82) and Mental fatigue (ß=.28) 
were enhanced. UPDRS did not inﬂ  uence Physical fatigue through its 
inﬂ  uence on depression
Discussion
Worse disease severity together with increased depression leads to worse 
General fatigue, Reduced activity and Mental fatigue. Worse disease 
severity separately causes worse Physical fatigue and depression alone 
causes more fatigue in the Reduced motivation domain. As currently 
there are no proved strategies to manage fatigue clinically, the recognition 
and the proper management of factors leading to fatigue is essential. 
Introduction
Fatigue is a frequent nonmotor symptom of Parkinson’s disease (PD) 
affecting 33-58% of PD patients (1-5) and remains persistent in 44% of PD 
patients (6). Only recently it was recognized as one of the most disabling 
features of PD (1,7), negatively inﬂ  uencing quality of life of PD patients 
(8,9).93
Fatigue is difﬁ  cult to deﬁ  ne, as it is a subjective experience occurring 
on a continuum that affects both a normal state and a pathological 
disturbances (1). Lou (2001) described fatigue as a state of extreme tiredness, 
weakness, lack of energy, exhaustion, which could be physical, mental, or 
both (10). Krupp et al. (1989) subdivided fatigue into two components, to 
a peripheral fatigue and a central fatigue (11). The ﬁ  rst refers to a fatigue 
after repeated muscle use or exercise, the latter occurs despite the absence 
of physical activities (12), and it is frequently observed in patients with 
chronic diseases (11).
Several studies have been performed to identify correlates of fatigue 
in PD. Sleep disorders (6), and anxiety (13,14) have been found to be 
related to fatigue, but not higher age (14), or gender (14).
Conﬂ  icting results have been found when an association between 
fatigue and disease severity was studied. Some studies did not ﬁ  nd 
correlations of fatigue with motor dysfunction (5,15), while others have 
found such a relationships (6), for both physical and mental fatigue 
domains (13).
Depression, another important nonmotor feature of PD, was found 
to be one of the factors related to fatigue (5), not only to mental but to 
physical fatigue domain as well (10; 13). Although the association between 
these two symptoms is problematic, as some overlap exists between these 
two conditions; fatigue is one of the diagnostic criteria for depression, 
it is clear that even nondepressed PD patients often suffer from fatigue, 
concluding that fatigue is an independent symptom from depression (6). 
The aim of our study was to examine how disease severity explains the 
different fatigue domains, how disease severity explains depression, and how 
disease severity explains via depression the different fatigue domains.
Methods
Patients
This cross-sectional study evaluated fatigue in a study population of 
190 patients with Parkinson’s disease. The patients were recruited from 
the hospitals and outpatients departments in the East Slovakian region 
between February 2004 and November 2005. All patients were diagnosed 
according to the United Kingdom Parkinson’s Disease Society Brain 
Clinical Criteria (16) and their mental abilities were assessed with the 
Mini- Mental State Examination (MMSE) (17). Exclusion criteria were 
deﬁ  ned as follows: 1. MMSE lower than 24; 2. disease duration longer than 
15 years; 3. presence of co-morbidity associated with the fatigue variable.94 CHAPTER  6
The study was approved by the local Ethics Committee. Informed 
consent was obtained from each patient. 
Data collection 
Data were collected by means of a mailed questionnaire comprising 
questions on socio-demographic background, medical history and 
current medication, as well as self-report questionnaires including the 
Multidimensional Fatigue Inventory (MFI) and Hospital Anxiety and 
Depression Scale (HADS). After three weeks all patients were interviewed 
in the structured interview and a neurologist assessed each patient’s 
disease severity with Uniﬁ  ed Parkinson’s Disease Rating Scale (UPDRS) 
Version 3.0 (18), including Hoehn and Yahr staging (19) and the Schwab 
and England disability scale (20). Caregivers were not allowed to make 
inputs into the questionnaires, patients who were not able to ﬁ  ll in the 
questionnaires by themselves because of motor impairment of their 
hands answered the questions during an oral interview (15 patients in 
our sample). 
Measures
Fatigue was assessed with the Multidimensional Fatigue Inventory 
(MFI). It is a 20-item self-report instrument designed and validated by 
Smets et al. (21). It measures ﬁ  ve fatigue domains: General fatigue, Physical 
fatigue, Mental fatigue, Reduced motivation, and Reduced activity. There 
are four items in each domain. The score on each item ranges from 1 (no 
fatigue) to 5 (very fatigued), so the score in each dimension ranges from 
4 (no fatigue) to 20 (highest possible fatigue). This instrument is used 
among patients with neurological diseases (10). The instrument was 
found to have good internal consistency with Cronbach’s alpha coefﬁ  cient 
of 0.89 in our sample. Cronbach’s alpha for the subscales were as follows: 
General fatigue 0.84, Physical fatigue 0.79, Reduced activity 0.80, Reduced 
motivation 0.71, Mental fatigue 0.82.
Depression was assessed using the Hospital Anxiety and Depression 
Scale (HADS). This self-administered scale simultaneously evaluates 
anxiety (HADS-A) and depression (HADS-D). It was designed to identify 
mood disorders in non-psychiatric outpatients. It consists of 14 items (7 
for the assessment of anxiety and 7 for the assessment of depression) 
scoring from 0 (no problem) to 3 (extreme problem). The cut-off values as 
proposed by the HADS developers (22) were applied in order to determine 
the proportion of patients considered unimpaired (not depressed, scoring 
≤7 on each subscale), possibly impaired (8–10 on each subscale), or 
probably impaired (≥11 on each subscale). Schrag et al. demonstrated good 
properties of HADS for screening purposes for depression in PD (23,24), 
with proposed cutoff scores of 23/24 for diagnostic purposes (24). In the 95
present study Cronbach’s alpha was 0.77 for the depression domain. 
The Uniﬁ   ed Parkinson’s Disease Rating Scale is a four-subscale 
combined scale (mental state, activities of daily living, motor examination, 
and complications). Two further instruments are attached to the UPDRS, 
namely: (a) a modiﬁ  ed Hoehn & Yahr Staging, an ordinal scale that is 
applied to gauge the course of disease over time; and (b) the Schwab & 
England Scale, a measure of functional independence providing scores 
that, though expressed as percentages, form an ordinal scale. Scores are 
obtained by interview and examination. It is currently used as a standard 
reference scale in clinical practice and research (18-20).
Basic socio-demographic data (age, gender) and disease duration 
were obtained from the structured interview. 
Statistical analysis
First, the demographic and clinical characteristics of the sample were 
described. Second, a path model was analyzed to test the estimates of the 
magnitude of the effects of disease severity and depression on the ﬁ  ve 
dimensions of fatigue, and to estimate whether our data ﬁ  t the proposed 
model. 
For model ﬁ  t we used multiple criteria as suggested by Bentler 
and Bonett (25). Using LISREL 8.7, we tested a recursive model (see 
Figure 1) in which direct pathways go from the background (exogenous) 
variable disease severity (UDPRS) to the ﬁ  ve dimensions of fatigue (MFI) 
and a pathway through which disease severity (UDPRS) inﬂ  uenced 
depression (HADS-D), from which pathways go to the ﬁ  ve dimensions 
of fatigue (MFI). To allow for mutual comparisons between the path 
coefﬁ  cients, the completely standardized solution was used. The analysis 
was performed with structural equation modelling using the maximum 
likelihood method. The ﬁ  t of the model was evaluated by means of (1) the 
comparative ﬁ  t index (CFI), (2) the normed ﬁ  t index (NFI), (3) the non-
normed ﬁ  t index (NNFI), (4) the standardized root mean square residual 
(SRMR) and (5) the root mean square error of approximation (RMSEA), 
in addition to (6) the chi-square (χ2) test; non-signiﬁ  cant χ2  indicating that 
a non-signiﬁ  cant amount of variance in the data remains unexplained. 
An adequate ﬁ  t of the model is indicated by NFI, NNFI and CFI≥.90, and 
SRMR<.08, RMSEA <0.05 and NFI >0.90 are considered to indicate good 
ﬁ  t.(26-33) (Table1).96 CHAPTER  6
Table 1. Parameter estimates of the path model relations between disease severity, depression and 
fatigue
χ2 df P RMSEA SRMR NFI NNFI CFI
Parameter estimates of the model 6.58 5 0.25 0.045 0.020 0.99 0.99 0.99
Critical values of parameter estimates >0.05 <0.06 <0.05 >.90 >.90 > .90
RMSEA - root mean square error of approximation; SRMR - standardized root mean square residual; 
NFI - normed fit index; NNFI - non-normed fit index; CFI - comparative fit index 
The model was evaluated by examining the parameter estimates and 
measures of overall ﬁ   t provided by LISREL. A residual correlation 
between depression and reduced motivation was allowed and also 
between dimensions of fatigue since standardized residuals indicated this 
correlation to exist (not depicted). Only the path coefﬁ  cients signiﬁ  cant at 
P < 0.05 level are depicted in the ﬁ  nal model.
Results
Out of 512 patients with PD meeting the inclusion criteria 29 did not wish 
to participate in the study; and 271 did not respond to the invitation. 
Total response rate was 37.1%. Out of those who agreed to participate, 
2 patients were eliminated because of the exclusion criteria, 10 patients 
were not included because of missing data (these patients agreed to 
participate in the study, ﬁ  lled in the questionnaire, but refused to come for 
the oral interview), and 190 remained for analysis. Non-responders did 
not differ signiﬁ  cantly from the analyzed group in age (mean difference 
1.6 yrs., SE=1.22; t=1.315; 95%CI -0.798 – 4.003) or gender (difference 
between proportions 0.095, SE = 0.066, 95% CI -0.0343–0.224) (difference 
of proportions test) (34). 
190 patients (93 men, 48.9%) completed the questionnaire and were 
interviewed, followed by examination by the neurologist. The mean age 
of the patients was 68.2±9.3 years. Mean age at disease onset was 59.5±11.1 
years. Mean disease duration was 6.4±4.7 years. Details of the clinical 
proﬁ  le and the study variables of the patients are shown in Table 2 and 
Table 3. 97
Table 2. Demographic and clinical description of the sample (n=190) 
Variable n, %, Mean±SD
1. Gender 
Male (n=93) 48.9%
Female (n=97) 51.1%
2. Age 68.2 ± 9.3
3. Disease duration 6.4 ± 4.7
4. UPDRS* total 36.3 ± 20.5
UPDRS III 16.1 ± 10.7
UPDRS IV 3.3 ± 3.3
5. H Y* 2.2 ± 1.1
≤ 2.0 115 (60.5%)
> 2.0  75 (39.5%)
6. S E* 69.3 ± 22.3
≤ 70% 88 (46.3%)
> 70% 102 (53.7%)
*UPDRS - Unified Parkinson’s Disease Rating Scale. H Y - Hoehn   Yahr Staging. S E - Schwab   
England Scale.
Table 3. Clinical description of the sample (n=190)
Variable Mean±SD n, %
1. HADS-D* 6.76 ± 3.7
≥ 11 27, 14.2%
2. MFI
General fatigue 13.7 ± 4.0  97, 51.1%
Physical fatigue 14.0 ± 3.6 103, 54.2%
Reduced activity 12.5 ± 3.8 71, 37.3%
Reduced motivation 10.7 ± 3.8 55, 29.0%
Mental fatigue 11.8 ± 3.8 70, 36.8%
3. Antiparkinsonian drugs used
L-dopa 24 (12.6%)
Dopamine agonists 43 (22.6%)
L-dopa + COMT inhibitors 40 (21.1%)
L-dopa + Dopamine agonists 27 (14.2%)
L-dopa + COMT inhibitor + Dopamine agonists 23 (12.1%)
Other 33  (17.4%)
HADS-D – Anxiety and Depression Scale, depression subscale. MFI – Multidimensional Fatigue Inventory98 CHAPTER  6
Figure 1 depicts the results of a path analysis with LISREL 8.7 (35) (Joreskog 
& Sorbom, 1993) showing the direct path between disease severity and 
depression and the ﬁ  ve domains of fatigue. Moreover, the mediated paths 
showing the inﬂ  uence of disease severity through enhanced levels of 
depression on domains of fatigue. 
Disease severity (UPDRS) increases the level of fatigue in General 
fatigue, Physical fatigue, Reduced activity and Mental fatigue, but not 
in Reduced motivation. Disease severity increased directly the level of 
depression through which levels of General fatigue (ß = .25), Reduced 
activity (ß = .31), Reduced motivation (ß = .82) and Mental fatigue (ß = 
.28) were enhanced. UPDRS did not inﬂ  uence Physical fatigue through its 
inﬂ  uence on depression.
Discussion
To our knowledge, this is the ﬁ  rst study performed in order to examine 
how depression and disease severity lead to the different domains of 
fatigue. Our results show that worse disease severity and worse depression 
both lead to worse General fatigue, Reduced activity and Mental fatigue. 
Worse disease severity separately causes worse Physical fatigue. Only 
depression (but not worse disease severity) causes more fatigue in the 
Reduced motivation domain.
Fatigue till now used to be overlooked, or considered as a consequence 
of muscle rigidity or higher age of PD patients. Only recently it was 
recognized as a frequent complaint of PD patients, and recognized as a 
nonmotor feature of PD. Although new questionnaires were developed 
to actively search for this problem, clinicians lack strategies how to 
manage it. Despite increased knowledge on fatigue its etiology is not 
fully understood, biological, as well as psycho-social factors may play a 
role. Our own research showed associations of fatigue with depression, 
anxiety and worse disease severity (36). The frequency of fatigue in our 
sample is consistent with the studies reporting the frequency of fatigue in 
33-58% of PD patients measured with the Nottingham Health Proﬁ  le, or 
with the Fatigue Severity Scale (2,5,6,15). 
Our results report worse disease severity to be an important factor 
leading to worse fatigue – not only in the physical domains (Physical 
fatigue, Reduced activity) but also in one mental domain (Mental fatigue), 
as until now it was generally considered to be to relatively independent 
of disease motor severity (5). Karlsen et al. did not show a relationship 
between disease severity and fatigue measured by Nottingham Health 
Proﬁ  le in a sample of 233 PD patients (5). Abe et al. in their relatively 
small study of 26 PD patients did not ﬁ  nd correlations between worse 99
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UPDRS and fatigue measured by Fatigue Severity Scale (FSS) (11,15). 
On the contrast, other studies found the association between worse 
UPDRS and worse fatigue. Alves et al. in their longitudinal study found 
fatigue measured by the generic Nottingham Health proﬁ  le to be related 
to disease severity (6), also in our previous research we found worse 
disease severity to be associated with worse fatigue, in all fatigue domains 
measured by MFI (13). 
The prevalence of depression was relatively low in our sample, 
that seem to be consistent with the recent papers on depression in PD. 
Reijnders (37) in his review paper reports its prevalence as 17% average, 
which is substantial, but less than the prevalence rates are usually quoted, 
e.g. Martinez-Martin et al. reported 48% prevalence of depression (38). 
Depression is not related to age, not to disease duration, and also not 
to disease severity. The prevalence depends on what is considered as 
“depression” because depression in the meaning of psychiatry can be from 
‘depressive mood’, through ‘minor depression’ till ‘major depression’. 
Different ranking scales do not differentiate all the depressive symptoms 
and some of them only score major or minor depression. Moreover, 
the difference between measures is also reported whether a study uses 
self reported questionnaires, or objective scales (37). In our research we 
decided to use the HADS, which was recently reported as being useful in 
Parkinson’s disease for screening of depression in PD patients, although 
not in adequately deﬁ  ning the severity of depression in this population 
(23). 
Several studies have shown the relationship between fatigue and 
depression. First results were from the study of Friedman et al. who found 
fatigue to be correlated with depression (3), also later studies of Karlsen et 
al. in a study of 233 PD patients, or our previous study in 150 PD patients 
having similar results (5,13). On the contrast, the study of Abe et al. in their 
relatively small sample of 26 PD patients did not ﬁ  nd correlations between 
depression and fatigue measured by FSS (15). In a study of Shulman et al. 
in a sample of 99 PD patients fatigue measured by Fatigue Severity Scale 
did not correlate with depression (14). 
Limitations
We had a relatively low response rate which is a limitation of our study. 
We suppose that this response rate is because patients with worse disease 
severity were not able to come for an interview. We suppose that our 
sample consisted of patients with a relatively better functional status. 
Our results thus cannot be generalized, but we suggest that even in this 
selected population of PD patients, fatigue is already a serious problem. 
We decided to use a generic measure with a multidimensional design 
instead of a disease speciﬁ  c fatigue measure, as its advantage is the 101
possibility of using a generic instrument for different patient groups and 
consequently, to compare them. 
Implications
Our study showed that the presence of depression and worse disease 
severity caused certain domains of fatigue. Thus proper management of 
the disease itself to improve disease severity is thus important. We stress 
the importance of the recognition of depression as its further treatment 
could improve fatigue. 
Further research should be performed, cross-sectional as well 
as longitudinal, to better understand these causal relationships. The 
answer to this question is important as it may inﬂ  uence the future clinical 
management of PD patients. 
Conclusions
Despite increasing knowledge demonstrating fatigue to be frequent 
and disabling feature of PD, it is still likely to be underrecognized by 
neurologists and thus lacking appropriate management. As currently 
there are no proved strategies to manage this problem clinically, the 
proper management of factors leading to fatigue is essential. 
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Chapter 7 
Discussion, clinical implications
General technological and scientiﬁ  c progress over the past decades have 
also affected health care and the values held there. Merely surviving is 
no longer the primary outcome of medical interventions, and the health 
care strategies have started to be oriented on the quality of life of the 
patients, especially for patients suffering from chronic diseases. Quality 
of life, together with morbidity and mortality, have thus become among 
the important measures of health care. 
Parkinson’s disease (PD) is a chronic neurological disorder. The 
current concept of PD has moved from just a ‘movement’ disorder to a 
movement disorder associated with a wide variety of nonmotor symptoms. 
The aim of this thesis was to explore the association of certain nonmotor 
presentations (fatigue, sleep disorders, mood disorders) and the quality of 
life of PD patients and to explore the character of the interrelations between 
these nonmotor symptoms based on the conceptual model of ICF (1). In 
this ﬁ  nal chapter the main ﬁ  ndings of this study will be summarized (7.1), 
discussed (7.2) and completed with practice implications and proposals 
and recommendations for future research (7.3).
7.1 Main  findings
7.1.1. Research question 1a
Is there a relationship between daytime and nighttime sleep disturbances and 
quality of life?
Sleep problems are well-known and well-described non-motor symptoms 
in PD. They play an important role in the lives of PD patients, negatively 
inﬂ  uencing their quality of life. They may result from uncontrolled motor 
complications, medication side-effects, or as a result of degeneration of 
the neuro-anatomical substrate responsible for the sleep-wake cycle (2).
When bivariate correlation analyses were performed, sleep disorders were 
signiﬁ  cantly correlated with depression and anxiety, with the observed 
associations stronger for anxiety than for depression. Looking more 
closely at quality of life (QoL), this was signiﬁ  cantly correlated with poor 
quality of nighttime sleep as well as with excessive daytime sleepiness. 
In addition, linear regression analyses were performed to evaluate the 
effect of the nighttime sleep disturbances measured with PSQI or daytime 
sleepiness measured with ESS as well as disease severity and mood 106 CHAPTER  7
disorders. Different results were obtained when analyzing separately for 
the model with PSQI and for the model with ESS. PSQI appeared to be a 
signiﬁ  cant predictor of QoL, but ESS was not.
Disease severity was another factor that signiﬁ  cantly inﬂ  uenced 
QoL in both models. However, our results show only anxiety as being 
a signiﬁ  cant factor associated with QoL in both the model with PSQI 
and the model with ESS. Depression was not signiﬁ  cant in either model. 
Our results thus showed an important contribution of nighttime sleep 
disturbances and anxiety to poor QoL.
7.1.2. Research question 1b
How are different fatigue domains related to different QoL domains and is there a 
difference between the physical and mental dimensions of QoL? 
Recent developments in fatigue in PD showed that fatigue is a 
multidimensional construct and that its dimensions are independent 
from each other (3). The presence of fatigue in PD patients predicts the 
worsening of all QoL domains. The most affected were the domains Bodily 
Discomfort, Mobility and Emotional well-being. Focusing on the different 
components of fatigue, mental domains (especially mental fatigue) were 
predictors of psychological QoL domains (Emotional well-being, Stigma, 
Social support, Cognition, Communication). Physical dimensions of 
fatigue (reduced activity) were predictors of the domains Mobility, ADL 
and Stigma. Fatigue in general appeared to be a predictor of the domains 
Emotional well-being and Bodily Discomfort. 
In addition to fatigue, worse disease severity is another important 
factor associated with worse QoL in all QoL domains except Cognition 
and Social support. Age, gender or disease severity did not show 
signiﬁ  cant relationships with QoL in general. Looking closely at different 
QoL domains, longer disease duration was associated with Emotional 
well-being, higher age with Cognition and female gender with Bodily 
discomfort. The present study was not controlled for depression and sleep 
disorders, as there is an overlap in symptomatology – sleep problems and 
fatigue are among the diagnostic criteria for depression, and vice versa.
7.1.3. Research question 2
Is there a relationship between nighttime or daytime sleep problems and fatigue, 
or are they independent from each other? 
Our results showed that neither sleepiness during the day, nor nocturnal 
sleep problems (quality of sleep) contributed to fatigue in any of the 
ﬁ  ve fatigue domains: general fatigue, physical fatigue, reduced activity, 
reduced motivation and mental fatigue. Depression, however, did 
contribute signiﬁ  cantly to all ﬁ  ve fatigue domains, and functional status 107
to four domains. These results thus mean that fatigue and sleepiness, or 
nighttime sleep disturbances, are distinct, but interrelated symptoms, 
though these terms are often used interchangeably, or under the general 
rubric of being ‘tired’. Our results thus conﬁ  rm that they are the distinct 
problems requiring different diagnostic or therapeutic strategies in 
response to patient complaints. 
7.1.3. Research question 3a
Do mood disorders or comorbidities contribute to the development of fatigue? 
Until now, fatigue has been considered a consequence of muscle rigidity 
or the higher age of PD patients. Despite increased knowledge about 
fatigue, its etiology is not fully understood, and biological as well as 
psychosocial factors may play a role. Although new questionnaires were 
developed to actively search for this problem, clinicians lack strategies 
for managing fatigue. Recognition of factors leading to fatigue and their 
proper management could improve QoL due to this nonmotor problem 
of PD patients. 
Using general linear model analysis, we found that mood disorders 
and worse disease severity are the most important factors associated 
with fatigue. Worse disease severity was related to all fatigue domains, 
as is depression. Anxiety was connected with Reduced motivation and 
General fatigue domains. 
We also expected comorbidities to inﬂ  uence fatigue, as fatigue was 
said to be frequent in patients after stroke or with cardiovascular diseases 
or diseases of the joints. Our results, however, did not show signiﬁ  cant 
associations of comorbidities with fatigue, and neither did age, gender, 
disease duration or education level.
7.1.4. Research question 3b
Is there a causal relation between disease severity and depression and fatigue; and 
between depression and fatigue themselves?
When looking at causal relations between depression and disease severity 
and fatigue using LISREL analysis, we found that worse disease severity 
and worse depression both lead to worse General fatigue, Reduced 
activity and Mental fatigue. Worse disease severity separately causes 
worse Physical fatigue. Only depression (but not worse disease severity) 
causes more fatigue in the Reduced motivation domain.
7.2  Discussion of the main findings
Our results showed that fatigue and nighttime sleep disturbances are 
important contributors to worse Quality of Life. Sleep disorders are 
among the most frequent complaints of PD patients; Martinez-Martin et al. 108 CHAPTER  7
reported insomnia in 45.7% of patients and excessive daytime sleepiness 
in 31.1% using the newly developed Nonmotor Symptoms Questionnaire 
in an observational, multicenter, international cross-sectional study (4). In 
a longitudinal study by Gjerstad et al. sleepiness was observed to increase 
its prevalence to 54% over an 8-year period (5). 
Our results showed both poor quality of sleep and sleepiness to have 
signiﬁ  cant associations with mood disorders, with associations stronger 
for anxiety than for depression.  While the relationship between sleep 
problems and depression has been well described in the literature (6), the 
observed connection between sleep problems and anxiety is relatively 
new. The ﬁ  rst association between depression and sleep disorders in PD 
patients was described by Tandberg et al. in 1998 in a community-based 
study, when depression, together with longer L-dopa therapy, correlated 
with the occurrence of sleep problems (7). Currently Buysse et al. 
reported in a longitudinal study a strong relationship between depression 
and insomnia and considered these two problems to be comorbid with 
each other, rather then sleep problems being secondary to depression (8). 
Anxiety and its associations with sleep disturbances were only recently 
studied by Borek et al. in a sample of 185 PD patients in 2006. They 
reported anxiety to have signiﬁ  cant correlations with excessive daytime 
sleepiness together with male gender and longer disease duration, but not 
with nighttime sleep problems (9).
When analyzing the inﬂ   uence of sleep problems on QoL, only 
Scaravilli et al., in a short report, published signiﬁ  cant correlations between 
poor nighttime sleep and poorer quality of life (10). The inﬂ  uence of 
daytime sleepiness has not been studied. We found signiﬁ  cant correlations 
between both excessive daytime sleepiness and poor nighttime sleep with 
overall QoL. Looking at regression analysis, different results were found, 
however. Nocturnal sleep disturbances were a signiﬁ  cant predictor of 
poor QoL, but excessive daytime sleepiness was not. In addition, mood 
disorders are important contributors to poorer QoL. Our results showed 
anxiety to be a signiﬁ  cant predictor of poorer QoL in both the model 
with nocturnal sleep problems and the model with excessive daytime 
sleepiness, but depression did not show signiﬁ  cant relationships, thus 
showing that anxiety is a much more important factor related to QoL 
compared with depression.
Fatigue is another important nonmotor feature of PD and is 
considered to be one of most disabling nonmotor features of the 
disease. Its etiology is not known, though biological changes in brain 
neurotransmitter mechanisms (11) or clinical and psychosocial variables 
may play a role (3,12).
Research in populations with a chronic neurological disease such 
as multiple sclerosis or amyotrophic lateral sclerosis has shown fatigue 
to be associated with lower levels of QoL. In PD patients the relationship 109
between fatigue and QoL was ﬁ  rst described in 2000 by Larsen et al., who 
reported more fatigue and poorer QoL in patients with PD compared to 
patients with diabetes mellitus or healthy individuals; they measured 
QoL using a generic instrument (13). 
When disease-speciﬁ  c QoL questionnaire was used, the presence of 
fatigue in PD patients showed to predict a worsening of all QoL domains 
(14). The most affected were the domains Bodily Discomfort, Mobility 
and Emotional Well-being. Focusing on the different components of 
fatigue, mental domains (especially Mental fatigue) were predictors of 
the psychological QoL domains (Emotional well-being, Stigma, Social 
support, Cognition, Communication), while the physical dimensions of 
fatigue (Reduced activity) were predictors of Mobility, ADL and Stigma 
domains. Fatigue in general appeared to be a predictor of the Emotional 
Well-being and Bodily Discomfort domains. 
In addition, worse functional status is another factor signiﬁ  cantly 
associated with worse QoL for all QoL domains except Cognition and 
Social Support. The relationship between worse functional status and 
worse QoL was shown by Karlsen et al. in a community-based sample 
of 111 patients; they did not ﬁ  nd that motor complications signiﬁ  cantly 
inﬂ  uenced QoL scores measured with the Nottingham Health Proﬁ  le 
(15). In contrast, Chapuis et al. using a disease-speciﬁ  c questionnaire on a 
sample of 143 PD patients, found worse motor scores were connected with 
worse scores for Mobility and ADL (16). The inﬂ  uence of sociodemographic 
variables on QoL have been discribed in the literature with conﬂ  icting 
results. Furthermore, we found longer disease duration to be associated 
with worse Emotional well-being, and female gender to be associated 
with worse Bodily Discomfort domain, a ﬁ  nding similar to those of Behari 
and Chapuis (16,17). 
Our next question was to evaluate how the presence of sleep 
disturbances, either during the daytime (excessive daytime sleepiness) or 
during the nighttime (poor quality of sleep), contribute to fatigue. All the 
variables are difﬁ  cult to distinguish from each other, as patients frequently 
describe all of them as simply “being tired”. However sleepiness, fatigue 
and apathy are separate nonmotor complaints requiring different 
therapeutical strategies and management.
We performed two separate series of multiple linear regression 
analyses using all the fatigue domains as dependent variables and 
excessive daytime sleepiness as an independent variable in the ﬁ  rst series 
of analyses and poor quality of sleep as an independent variable in the 
second series of analysis. Both were controlled for age, gender, disease 
duration, functional status and depression. We decided against controlling 
for depression to avoid a bias, as depression contributes to the presence of 
fatigue even in our own results. 
Our results showed that fatigue is independent from both excessive 110 CHAPTER  7
daytime sleepiness and poor quality of sleep during nighttime. Fatigue 
is far more inﬂ  uenced by depression and worse functional status. This 
knowledge is relatively new, as previous research was performed by 
Alves et al. (18), who compared PD patients with and without excessive 
daytime sleepiness and found that both groups had high levels of fatigue, 
indicating the possibility that fatigue may result from sleepiness, but not 
necessarily so. The relative independence of fatigue and sleepiness was 
also reported for multiple sclerosis patients in a study by Kaynak et al. 
(19), although these two populations are difﬁ  cult to compare as MS and 
PD affect different age groups. 
The identiﬁ  cation of possible treatable factors leading to fatigue is 
important, as their proper management may thus decrease fatigue. For 
this reason we evaluated depression and anxiety; comorbidities such as 
cardiovascular diseases, diseases of bones and joints, renal, and hepatal 
diseases; functional status; disease duration; and the sociodemographic 
variables age, gender, and level of education. A general linear model 
analysis was used to evaluate 5 different fatigue domains as dependent 
variables. Our study showed that neither age, gender, disease duration nor 
level of education were related to any fatigue dimension. Worse functional 
status was signiﬁ   cantly associated with all the fatigue domains, the 
strongest for the physical fatigue and weakest for the reduced motivation 
domain. Depression was signiﬁ  cantly related to all the fatigue domains, 
mental as well as physical, while anxiety showed relations with General 
Fatigue and Reduced Motivation. 
Associations of functional status with fatigue are in contrast with 
previous studies. A study by Karlsen et al. (20) found no relationship 
between disease severity measured by UPDRS and fatigue in a sample of 
233 PD patients. The ﬁ  ndings are similar to those of a study by Lou et al. 
(3), who in a sample of 39 PD patients did not ﬁ  nd correlations between 
disease severity and any of the dimensions of the MFI. Concerning 
depression, our ﬁ  ndings of the association of depression with all the 
fatigue domains are partly similar to the ﬁ  ndings of Lou et al. (3); in their 
sample of 39 PD patients depression was related to the mental dimensions 
of fatigue (mental fatigue), but not with physical fatigue. 
Comorbidities did not show signiﬁ  cant associations with fatigue, 
although many patients with cardiovascular disease, stroke or rheumatoid 
arthritis report higher incidence of fatigue (21-23). These results thus 
support ﬁ  ndings that fatigue is an independent nonmotor feature of 
Parkinson`s disease. 
The next step for the evaluation of factors associated with fatigue 
was the analysis of possible causal relationships between depression, 
functional status and fatigue. For this reason we performed LISREL 
analysis to examine how disease severity explains the different fatigue 
domains, how disease severity explains depression, and how disease 111
severity explains via depression the different fatigue domains. To our 
knowledge such research has not previously been performed. Our results 
showed that worse disease severity and worse depression both lead to 
worse General fatigue, Reduced activity and Mental fatigue. Worse disease 
severity separately causes worse Physical fatigue. Only depression (but 
not worse disease severity) causes more fatigue in the Reduced motivation 
domain.
There were limitations to the present research. Our sample consisted 
mostly of patients who were able to come for the examination and 
interview – either alone or with a family member as a companion – so we 
suppose that non-responders were patients with worse functional status, 
mostly bedridden. Despite the rather low response rate, in this selected 
population fatigue, sleep disorders and quality of life of PD patients is 
already a serious problem, so we expect this to be even worse in the total 
PD patients group.
7.3  Recommendations for research
The results of this thesis show only some of the interesting associations 
between nonmotor symptoms of Parkinson’s disease and quality of life of 
PD patients, as well as the interrelationships between nonmotor features 
themselves.
It would be interesting to explore these relationships in various 
stages of the disease. Patients in an early stage report different problems 
and require a different approach than patients with advanced Parkinson’s 
disease. This later stage is characterized by the presence of motor 
complications that could enter into the previously developed relationships, 
e.g. between depression and fatigue or sleep disorders and QoL, and 
inﬂ   uence the behavior of certain variables (e.g. motor complications, 
if they occur during nighttime, may be associated with worsening of 
sleep problems and thus contribute to worsening of QoL). Patients 
with advanced PD thus may represent a sample with a different kind of 
relationships between variables. So a future study could concentrate on 
two separate analyses in these two different PD patient populations using 
comparative statistics.
Our research was based on cross-sectional data. However 
longitudinal data could provide us with more satisfactory information 
and allow us to explain the causal relationships between the variables. 
One way to ﬁ  nd the answers to these questions is to observe patients 
through a prospective study in which individuals are examined several 
times. Our data showed that relationships between variables are very 
complex, and that multidirectional longitudinal data could explore the 112 CHAPTER  7
causal pathways. We expect, based on our response rate in this study, a 
selective loss to follow up in a longitudinal study. Besides, as PD patients 
become older, they will have newly developed comorbidities that might 
inﬂ  uence some of the variables of interest, like fatigue.
As the exact etiology of certain nonmotor symptoms is not clear, 
psychological factors may possibly play a role. It might also be of interest 
to investigate how some personal characteristics interact with nonmotor 
symptoms like fatigue or some sleep problems. The Type D personality 
proﬁ  le or the Eysenck personality test could be used for such research in 
a cross-sectional as well as a longitudinal study.
Very interesting information on quality of life could be provided by a 
multicenter study – the observations of Slovak patients in the area of East 
Slovakia and Dutch patients in Groningen, for example. As the patients 
in both countries have similar access to healthcare and medication, the 
observed differences in the different dimensions of quality of life could 
be explained by cross-cultural differences in non-medical factors between 
the cohorts. 
7.4 Implications for practice
Sleep disorders
An interview with a PD patient should include sleep habits, presence of 
nocturnal sleep disruption (snoring, respiratory pauses, movements in 
sleep) and a complete drug history. The Epworth Sleepiness Scale (ESS) 
provides a useful tool that is practical in an ofﬁ  ce setting for evaluating the 
presence and severity of EDS. Additional evaluation for nocturnal sleep 
disturbances, including sleep apnea or PLMD, may identify those patients 
who are sleepy secondary to nighttime sleep deprivation. An evaluation 
by PSQI and lab tests like polysomnography and a multiple sleep latency 
test can diagnose these primary sleep disorders (24,25). PD patients who 
are sleepy are at increased risk of trafﬁ  c accidents and should be cautioned 
not to drive (25).
Evaluation of sleep habits and their improvement is an important part 
of therapy. Treatment of daytime sleepiness in PD includes the assessment 
of a patient for possible nocturnal sleep disturbances. Sleep apnea, periodic 
limb movements and other disorders that disrupt nocturnal sleep should 
be considered, as should the side-effects of medications. If the onset of 
EDS follows initiation or increased dosage of dopaminergic therapy, either 
a reduction in dose or a switch to another drug may be necessary (26). If 
sleepiness is persistent and not responsive to medication adjustments, the 
use of stimulants may be warranted. Modaﬁ  nil, a stimulant drug useful in 113
narcolepsy, may be of modest beneﬁ  t, as has been shown in two controlled 
studies in a small number of PD patients with excessive daytime sleepiness 
(27,28).
Anxiety
Some patients with anxiety disorders related to PD may beneﬁ  t from 
behavior modiﬁ  cation techniques. However, pharmacologic therapy is 
often needed. Certain antidepressants are approved for the treatment of a 
range of anxiety disorders; these agents include paroxetine, escitalopram 
and venlafaxine. Benzodiazepines should be considered for more severe 
anxiety, although patients should be counseled in regard to potential 
adverse effects, such as sedation, further cognitive deterioration and 
balance problems, which may increase the risk of falls. Similar to the 
general population, SSRIs may be helpful in the treatment of panic 
disorder, social phobia and generalized anxiety disorder in PD.
Depression
In some patients, especially those with early PD, treatment with 
antiparkinsonian medications may improve depression. Unfortunately, 
well-designed clinical trials have not been performed. Otherwise, the 
treatment of depression in PD is similar to the treatment used in non-PD 
cases of depression. 
As with all central nervous system–active medications used to 
treat the associated features of PD, it is important to monitor motor 
functioning if an antidepressant is initiated. Tricyclic antidepressants 
are effective in treating depression in PD and may even reduce motor 
symptoms (29). Treatment with TCAs is restricted by adverse effects, such 
as the worsening of cognitive functions. PD patients also have increased 
susceptibility to anticholinergic side effects, including delirium and 
hypotension. Most PD specialists use SSRI agents as a ﬁ  rst-line treatment, 
including ﬂ  uoxetine, sertraline, paroxetine, and ﬂ  uvoxamine, because of 
the lack of anticholinergic and sedative side effects. In the most severe 
cases of depression in PD, electroconvulsive therapy, as was proposed by 
Lemke, may be of beneﬁ  t (29).
Caring for patients is a task that becomes increasingly complex 
and demanding as the severity of disease progresses. Patient-centered 
treatment should include: early referral to a specialist, with regular 
reviews; multidisciplinary assessment, with access to a range of therapies; 
management with appropriate medication; and management of non-
motor symptoms, including depression, anxiety, sleep disturbances 
and other. Patients should receive education and information about the 
disease. Building a support network of general practitioners, specialists 114 CHAPTER  7
in movement disorders ﬁ  eld, nursing homes and family are extremely 
essential for improving quality of life of PD patients. 
General considerations
In PD patients it is not only the objective motor deﬁ  cits but rather the 
mechanisms to cope with the impaired functions and subjective experience 
of deﬁ  cits that determine mainly the quality of life and subjective well-
being. Interpersonal psychotherapy, cognitive therapy, training of social 
functions and relaxation therapy appear to positively affect quality of life 
and the course of PD.
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Summary
Parkinson’s disease (PD) is a slowly progressive disease characterized 
by its motor and only recently recognized nonmotor features. This thesis 
focuses on fatigue, sleep problems and mood disorders, on the relationships 
between these nonmotor features and their impact on quality of life (QoL) 
of PD patients. QoL has become one of the most important measures 
and constructs for evaluating more comprehensively the outcomes of a 
chronic disease. 
Previous research in this ﬁ   eld has mostly been oriented on 
descriptive data showing that PD patients report worse QoL than the 
general population. Later determinants of worse QoL were studied, with 
an interest in typical motor problems and sociodemographic variables. 
For this reason the Global Parkinson’s Disease Survey Committee was 
established in 2002. The results of this multinational cross-sectional study 
showed worse disease severity, a medication regime with only L-dopa and 
the presence of depression to signiﬁ  cantly worsen QoL. This study was 
thus the ﬁ  rst to evaluate the inﬂ  uence of nonmotor PD features on QoL. 
Recent research has also shown that the motor complications of L-dopa, 
pain or cognitive decline can worsen QoL.
This thesis tries to answer to following research questions: Is there 
a relationship between daytime and nighttime sleep disturbances and 
different QoL domains? How are different fatigue domains related to 
different QoL domains and is there a difference between physical and 
mental dimensions of QoL? Is there a relationship between nighttime or 
daytime sleep problems and fatigue, or are they independent from each 
other? Do mood disorders or comorbidities contribute to the development 
of fatigue? Is there a causal relation between disease severity and 
depression and fatigue; and between depression and fatigue? 
The aim of Chapter 2 was to evaluate the impact of sleep disorders 
on QoL. Sleep problems are frequent in PD patients and they may occur 
during the nighttime as well as during the daytime. They may result 
from uncontrolled motor complications, medication side-effects, or as a 
result of the degeneration of the neuro-anatomical substrate responsible 
for the sleep-wake cycle. In our sample 73.1% of patients reported poor 
nighttime sleep and 23.7% reported excessive daytime sleepiness (ESS). 
We performed two separate linear regression analyses to evaluate the 
effect of poor night time sleep or excessive daytime sleepiness on quality 
of life, controlled for depression, anxiety and functional status. We 
found that poor nighttime sleep is a signiﬁ  cant contributor to poor QoL, 118 SUMMARY
but excessive daytime sleepiness is not. In addition, worse functional 
status and anxiety showed signiﬁ  cant relationships with poor QoL, but 
depression was not signiﬁ  cant in either model. Our results thus showed 
an important contribution of nighttime sleep disturbances and anxiety to 
poor QoL.
Chapter 3 examined the inﬂ  uence of fatigue on QoL. Fatigue is 
considered to be a multidimensional construct with mental and physical 
components which are independent from each other. It is considered to 
be one of the most disabling nonmotor symptoms of PD patients, being 
reported by one-third of PD patients. The presence of fatigue was associated 
with worse QoL in all domains – with Bodily Discomfort, Mobility and 
Emotional Well-being as the most affected. Looking closer at different 
fatigue components, the mental components (especially Mental fatigue) 
were associated with more psychological QoL domains (Emotional Well-
being, Stigma, Social Support, Cognition, Communication), and the 
physical components (Reduced activity) were related to more physical QoL 
domains (Mobility, Activities of Daily Living and Stigma). Additionally, 
worse functional status was associated with worse QoL scores for all the 
domains except Social Support and Cognition; higher age was related with 
worse Cognition; longer disease duration with Emotional Well-being; and 
female gender with the Bodily Discomfort domains.
Chapter 4 deals with relationships between fatigue and sleep 
disturbances. We performed a series of linear regression analyses to 
evaluate the association of excessive daytime sleepiness or poor quality 
of sleep with different fatigue components. Our results showed that 
sleep disturbances (either daytime or nighttime) do not have signiﬁ  cant 
relationships, thus indicating that these two problems – fatigue and sleep 
problems in PD patients – are independent from each other. 
The aim of Chapter 5 was to evaluate factors associated with fatigue. 
Basic sociodemographic variables (age gender, disease duration, level 
of education), mood disorders (anxiety and depression), comorbidities 
(measured by Charlson index) and functional status were all entered into 
general linear model analysis. Our result showed worse disease severity 
and depression to have signiﬁ  cant relationships with worse scores for 
all the fatigue components. Anxiety was associated with more serious 
General fatigue and Reduced motivation. 
Chapter 6 evaluates the causal relationships between depression, 
functional status and fatigue. For this reason LISREL analysis was 
performed in order to examine how functional status explains depression, 
and how disease severity explains via depression the different fatigue 
components. We found that worse functional status and worse depression 
both lead to worse General fatigue, Reduced activity and Mental fatigue. 
Worse disease severity alone caused worse Physical fatigue, and worse 
depression alone caused more fatigue in the Reduced motivation 119
component. 
A limitation, mentioned in the Discussion, is that our research was 
based on cross-sectional data. However, longitudinal data could provide 
us more satisfactory information for explaining the causal relationships 
between the variables. Future research could also be concentrated on the 
evaluation of the different PD population groups – patients with early PD 
and with advanced PD. 
Nonmotor symptoms are universal features of idiopathic PD and 
involve dysfunction in the neuropsychiatric, sensory and autonomic 
domains. Together, they add signiﬁ  cantly to the overall disability caused 
by PD and are critical determinants of health-related quality of life. In 
the era of effective symptomatic therapies for the motor symptoms of PD, 
non-motor dysfunction has developed into a major prognostic factor for 
overall disease burden and everyday function in PD. 
We stress the importance of recognizing the different aspects of 
nonmotor features of Parkinson’s disease. The recognition of possible 
treatable problems and their proper management is extremely important 
as they may lead to improvement of another nonmotor feature and may 
thus result in the improvement of the quality of life of PD patients. 120 SAMENVATTING121
Samenvatting
De Ziekte van Parkinson (PD) is een langzaam progressieve ziekte 
gekarakteriseerd door zijn motorische en meer recentelijk herkende niet-
motorische verschijnselen. Dit proefschrift richt zich op vermoeidheid, 
slaap problemen en stemmingsstoornissen, op de relaties tussen deze 
niet- motorische verschijnselen en hun invloed op de levenskwaliteit 
van Parkinsonpatiënten. Levenskwaliteit is een van de meest belangrijke 
maten om op een geïntegreerde manier de gevolgen van een chronische 
zieke te evalueren.
Vroeger onderzoek was meestal gericht op beschrijvende data die 
lieten zien, dat PD patiënten een slechtere levenskwaliteit hadden dan de 
algemene bevolking. Later werden determinanten van de verslechterde 
levenskwaliteit onderzocht, vooral de variabelen die afgeleid waren 
van de typische motorische verschijnselen en de sociodemograﬁ  sche 
variabelen. Mede ter ondersteuning hiervan werd in 2002 de Global 
Parkinson’s Disease Survey Committee opgericht. De resultaten van het 
multinationale cross-sectionele onderzoek lieten zien dat een grotere 
ziekte-ernst, een medicatieregiem met alleen L-dopa, en de aanwezigheid 
van depressie de levenskwaliteit signiﬁ   cant negatief beinvloeden. In 
dit onderzoek werd voor het eerst de invloed van niet-motorische PD 
verschijnselen op de levenskwaliteit onderzocht. Meer recent onderzoek 
laat zien dat ook de motorische complicaties van de L-dopa therapie, pijn 
of cognitieve achteruitgang de levenskwaliteit doen verslechteren. 
In dit proefschrift wordt gezocht naar een antwoord op de volgende 
vragen. 
-   Bestaat er een verband tussen slaapproblemen gedurende de nacht, sla-
perigheid overdag en de verschillende domeinen van levenskwaliteit?
-   Hoe is het verband tussen de verschillende domeinen van moeheid 
en de verschillende domeinen van levenskwaliteit en is er een ver-
schil tussen de fysieke en mentale dimensies van levenskwaliteit? 
-   Is er een verband tussen slaapproblemen gedurende de nacht of sla-
perigheid overdag en moeheid of zijn ze onafhankelijk van elkaar? 
-   Verergeren stemmingsstoornissen of comorbiditeit de ontwikkeling 
van moeheid? 
-   Is er een causaal verband tussen ziekte-ernst en depressie en moe-
heid; en tussen depressie en moeheid?
In Hoofdstuk 2 wordt het verband tussen slaapstoornissen en 
levenskwaliteit beschreven. Slaapstoornissen komen vaak voor bij PD 122 SAMENVATTING
patiënten, zowel ’s nachts als overdag. Als mogelijke oorzaken worden 
genoemd ongecontroleerde motorische complicaties, bijwerkingen van 
medicatie, of de degeneratie van het neuro-anatomisch substraat dat 
verantwoordelijk is voor het slaap-waak ritme. In onze steekproef noemde 
73.1% van de patiënten slaapproblemen gedurende de nacht en 23.7% noemde 
slaperigheid overdag. Met behulp van lineaire regressie analyse werd het 
effect gemeten van slaapproblemen gedurende de nacht respectievelijk 
slaperigheid overdag op levenskwaliteit, gecontroleerd voor depressie, angst 
en ziekte-ernst. Slaapproblemen gedurende de nacht droegen signiﬁ  cant bij 
aan een lage levenskwaliteit, maar slaperigheid overdag niet. Daarenboven 
bestonden er signiﬁ  cante verbanden tussen ziekte-ernst en angst en lage 
levenskwaliteit, maar depressie was in beide modellen niet signiﬁ  cant. 
Onze resultaten lieten dus een belangrijke bijdrage van slaapproblemen 
gedurende de nacht en angst aan lage levenskwaliteit zien.
Hoofdstuk 3 richt zich op het verband tussen moeheid en 
levenskwaliteit. Moeheid is een multidimensioneel construct met mentale 
en fysieke componenten die onafhankelijk van elkaar zijn. Moeheid wordt 
verondersteld één van de meest invaliderende niet-motorische symptomen 
bij PD patiënten te zijn, gemeld door eenderde van de PD patiënten. De 
aanwezigheid van moeheid was geassocieerd met alle domeinen van 
levenskwaliteit, waarvan Bodily Discomfort, Mobility en Emotional 
Well-being het meest werden beïnvloed. Bij analyse van de moeheid 
componenten bleek dat de mentale componenten (in het bijzonder 
Mental fatigue) was gerelateerd aan de meer psychische domeinen van 
levenskwaliteit (Emotional Well-being, Stigma, Social Support, Cognition, 
Communication), en dat fysieke componenten (Reduced activity) vooral 
gerelateerd waren aan de meer fysieke domeinen van levenskwaliteit 
(Mobility, Activities of Daily Living, en Stigma). Daarenboven was een 
grotere ziekte-ernst gerelateerd met lagere levenskwaliteitscores op alle 
domeinen, uitgezonderd Social Support en Cognition. Hogere leeftijd was 
gerelateerd met slechtere scores voor Cognition, een langere ziekteduur 
met Emotional Well-being en het vrouwelijk geslacht met het domein 
Bodily Discomfort.
Hoofdstuk 4 gaat in op het verband tussen slaapstoornissen en 
moeheid. Met behulp van lineaire regressie analyse werd nagegaan 
of er een verband was tussen slaapproblemen gedurende de nacht en 
slaperigheid overdag met de verschillende componenten van moeheid. 
Onze resultaten lieten zien dat de slaapstoornissen (zowel gedurende de 
nacht als overdag) geen signiﬁ  cant verband hebben met moeheid, hetgeen 
erop wijst dat deze twee problemen – moeheid en slaapstoornissen bij PD 
patiënten – onafhankelijk van elkaar zijn.
In Hoofdstuk 5 komen de met moeheid samenhangende factoren 123
aan de orde. Met behulp van sociodemograﬁ  sche variabelen (leeftijd, 
geslacht, onderwijsniveau), ziekte gerelateerde variabelen (ziekteduur, 
ziekte-ernst), stemmingsstoornissen (angst en depressie) en comorbiditeit 
(uitgedrukt in de Charlson index) werd een General Linear Model analyse 
uitgevoerd. Onze resultaten lieten zien dat een hogere ziekte-ernst en 
depressie signiﬁ  cante verbanden toonden met slechtere scores op alle 
vijf componenten van de moeheid; angst was alleen geassocieerd met een 
toegenomen General fatigue en Reduced motivation. 
In Hoofdstuk 6 worden de causale verbanden tussen depressie, 
ziekte-ernst en moeheid onderzocht. Met dit doel is een LISREL-
analyse uitgevoerd met het doel te onderzoeken hoe ziekte-ernst 
depressie verklaart, en hoe ziekte-ernst via depressie de verschillende 
moeheidcomponenten verklaart. Wij vonden dat een toegenomen ziekte-
ernst en depressiviteit beide leidden tot meer General fatigue, Reduced 
activity en Mental fatigue. Toegenomen ziekte-ernst alleen leidde tot 
toegenomen Physical fatigue en toegenomen depressiviteit alleen leidde 
tot meer Reduced motivation. 
Een beperking, genoemd in de Discussie, is dat ons onderzoek was 
gebaseerd op cross-sectionele data. Longitudinale data zouden ons in de 
toekomst betere data kunnen verstrekken om in staat te zijn de causale 
verbanden tussen de variabelen beter te onderzoeken. Toekomstig 
onderzoek zou eveneens gericht moeten zijn op het verloop van PD bij 
verschillende patiëntengroepen - ‘vroege’ PD patienten en patienten met 
een meer gevorderd stadium van PD.
Niet-motorische symptomen zijn universele verschijnselen van PD 
en hebben betrekking op neuropsychiatrische, sensorische en autonome 
domeinen. Samenvattend vormen ze een signiﬁ  cante toevoeging aan de 
bestaande algemene beperkingen die door PD wordt veroorzaakt en ze zijn 
belangrijke determinanten van gezondheidsgerelateerde levenskwaliteit. 
In het tijdperk van de toegenomen effectieve symptomatische behandeling 
van de motorische symptomen van PD hebben de niet-motorische 
symptomen zich ontwikkeld tot een belangrijke prognostische factor voor 
de algemene ziektelast van PD en het alledaagse functioneren van PD-
patienten.
Wij leggen de nadruk op het belang van het herkennen van de 
verschillende aspecten van de niet-motorische verschijnselen van PD. Het 
herkennen van mogelijk behandelbare problemen is van uitzonderlijk 
groot belang, omdat het kan leiden tot een verbetering van zulke niet-
motorische verschijnselen en derhalve zal resulteren in het verbeteren van 
de levenskwaliteit van PD patienten.124 ZHRNUTIE125
Zhrnutie
Kvalita života (quality of life, QoL) sa v posledných rokoch stala 
významným meradlom v starostlivosti o pacientov. Hodnotenie 
samotného pacienta, najmä v oblasti kvality života súvisiacej so zdravím je 
považované za dôležitý výstup pri vyhodnocovaní a porovnávaní vplyvu 
jednotlivých ochorení, rôznych terapeutických postupov, ako aj celkového 
manažmentu zdravotnej starostlivosti jednotlivých pacientov. 
Parkinsonova choroba (PD) je pomaly progredujúce ochorenie 
charakterizované jednak svojimi typickými motorickými aj iba nedávno 
rozpoznanými nemotorickými prejavmi. Táto práca sa cielene venuje práve 
nemotorických prejavom PD, a to únave, spánkovým poruchám, poruchám 
nálady, skúma vzájomné vzťahy medzi týmito prejavmi a skúma aj vplyv 
týchto prejavov na kvalitu života pacientov s Parkinsonovou chorobou. 
Predchádzajúce výskumy v oblasti kvalita života pacientov s PD boli 
viac menej orientované na opis vplyvu samotného ochorenia. Výsledky 
tejto štúdie ukázali, že pacienti s PD majú horšiu kvalitu života v porovnaní 
v ostatnou populáciou. Iné štúdie sa venovali faktorom ovplyvňujúcim 
QoL z pohľadu typických motorických prejavov a sociodemograﬁ  ckých 
charakteristík. Za týmto účelom bola r. 2002 zostavená medzinárodná 
komisia skladajúca sa z odborníkov v oblasti Parkinsonovej choroby - Global 
Parkinson’s Disease Survey Committee. Táto na základe dát z prierezovej 
medzinárodnej multicentrickej štúdie zistila, že zhoršený funkčný 
stav, terapeutický režim podávania len L-dopy a prítomnosť depresie 
významne zhoršujú kvalitu života. Táto štúdia bola zároveň aj jednou 
z prvých prác zaoberajúca sa vplyvom nemotorického príznaku na QoL. 
Neskoršie práce potvrdili naj negatívny vplyv motorických komplikácii 
liečby L-dopou, prítomnosť bolesti alebo zhoršený kognitívnych funkcií 
na zhoršenie kvality života.
V našej práci sa pokúšame zodpovedať na nasledujúce otázky: 
Existuje vzťah medzi poruchami denného či nočného spánku a rôznymi 
oblasťami kvality života? Akým spôsobom rôzne dimenzie únavy 
ovplyvňujú rozdielne domény kvality života a existuje rozdiel medzi 
fyzickými a mentálnymi doménami kvality života? Jestvuje vzťah medzi 
poruchami nočného spánku a nadmernou dennou spavosťou a únavou, 
alebo sú to navzájom nezávislé nemotorické prejavy Parkinsonovej 
choroby? Majú poruchy nálady alebo komorbidity vplyv na vznik únavy? 
Existuje príčinný vzťah medzi závažnosťou ochorenia a depresiou 
a únavou, resp. medzi depresiou a únavou? 126 ZHRNUTIE
Cieľom kapitoly 2 bolo vyhodnotenie vplyvu spánkových porúch 
na kvalitu života pacientov s Parkinsonovou chorobou. Pacienti s PD 
často udávajú prítomnosť poruchy spánku a to tak v noci (teda poruchy 
nočného spánku) ako aj cez deň v podobe nadmernej dennej spavosti. 
Etiológia spánkových porúch nie je zatiaľ jasná, môže sa jednať o následok 
degenerácii v neuroanatomických substrátoch zodpovedných za cyklus 
spánok-bdenie, môže sa jednať o komplikácie antiparkinsonskej liečby 
(najmä podávania dopamínových agonistov), eventuálne môžu byť 
následkom motorických komplikácií počas noci (napr. dystónia v ranných 
hodinách, zhoršenie rigidity uprostred noci s nemožnosťou otočenia sa na 
posteli ai.). V našej vzorke sme poruchy nočného spánku zistili u 73,1% 
pacientov a nadmernú dennú spavosť u 23.7% pacientov. Na zistenie 
vplyvu poruchy nočného spánku a nadmernej denne spavosti boli 
realizované 2 nezávislé analýzy pomocou lineárnej regresie. Analýza bola 
kontrolovaná pre depresiu, anxietu a funkčný stav. Výsledky ukázali, že 
poruchy nočného spánku významne zhoršujú kvalitu života, ale nadmerná 
denná spavosť štatisticky signiﬁ  kantný význam nemala. Podobne sme 
nezistili signiﬁ  kantný vplyv depresie, ani v modeli pre nočné poruchy 
spánku ani pre nadmernú spavosť, naopak anxieta preukázala významný 
vplyv na zhoršenie kvalitu života v oboch analýzach.
Kapitola 3 je venovaná vplyvu únavy na kvalitu života. Z hľadiska 
únavy sa jedná o konštrukt pozostávajúci z viacerých zložiek – mentálnych 
aj fyzických, ktoré sú navzájom nezávislé. Únava je považovaná za jeden 
z najnepríjemnejších nemotorických prejavov Parkinsonovej choroby, na 
ktorú sa sťažuje približne jedna tretina pacientov s PD. Na základe analýzy 
lineárnou regresiou, sme zistili, že únava vplývala na všetky dimenzie 
kvality života, pričom najviac na domény telesného dyskomfortu (Bodily 
Discomfort), mobility (Mobility) a Emocionálnej pohody (Emotional Well-
being). Pri bližšom pohľade na rôzne komponenty únavy sme odhalili 
vplyv mentálnych komponent únavy (najmä mentálne únavy – Mental 
fatigue) na zhoršenie viac psychologických domén QoL - emocionálnej 
pohody (Emotional Well-being), pocit stigmy (Stigma), sociálnej podpory 
(Social Support), kognície (Cognition) a komunikácie (Communication), 
a vplyv fyzických komponent únavy (najmä redukcie aktivity (Reduced 
activity) na zhoršenie fyzických QoL domén – mobility (Mobility), aktivít 
každodenného života (Activities of Daily Living) a stigmy (Stigma). 
Podobne zhoršený funkčný stav bol spojený so zhoršením QoL v každej 
z domén okrem sociálnej podpory (Social Support) a kognície (Cognition). 
Vyšší vek bol spojený so zhoršením kognície (Cognition), dlhšie trvanie 
ochorenia s horšou kvalitou života v oblasti emočnej pohody (Emotional 
Well-being) a ženské pohlavie súviselo s pocitom telesného dyskomfortu 
(Bodily Discomfort). 127
Nasledujúce kapitoly sa venujú vzájomným vzťahom medzi 
nemotorickými prejavmi. V kapitole 4 skúmame vzťah medzi 
spánkovými poruchami a únavou. Cestou lineárnej regresie sme skúmali 
v 2 nezávislých sériách analýz jednak vzťah porúch nočného spánku 
voči rôznym komponentom únavy a jednak vplyv nadmernej dennej 
spavosti na rôzne komponenty únavy. Zistili sme, že ani poruchy nočného 
spánku, ani nadmerná denná spavosť nemá štatisticky signiﬁ  kantný 
vzťah s únavou, čo naznačuje, že tieto nemotorické prejavy sú navzájom 
nezávislé od seba. 
Cieľom 5 kapitoly bolo skúmať faktory, ktoré vplývajú na rozvoj 
únavy pacientov s PD. Do analýzy sme dali základné socio-demograﬁ  cké 
ukazovatele (vek, pohlavie, dĺžka trvania ochorenia a výška dosiahnutého 
vzdelania), poruchy nálady (depresia a anxieta), prítomnosť komorbidít 
a funkčný stav. Výsledky ukázali, že horší funkčný stav a prítomnosť 
depresie významne súvisela so všetkými komponentmi únavy. Prítomnosť 
anxiety mala významný vzťah s komponentmi všeobecnej únavy (General 
fatigue) a redukovanej motivácie (Reduced motivation). 
V kapitole 6 bola pozornosť sústredená na vysvetlenie kauzálnych 
vzťahov medzi únavou, depresiou a funkčným stavom. Pomocou LISREL 
analýzy sme chceli zistiť akým spôsobom horší funkčný stav vysvetľuje 
depresiu a akým spôsobom horší funkčný stav prostredníctvom depresie 
vysvetľuje rôzne komponenty únavy. Výsledkom analýzy bolo zistenie, 
že horší funkčný stav spoločne s prítomnou depresiou vedú k zhoršeniu 
únavy vo všeobecnosti (General fatigue), redukovanej aktivity (Reduced 
activity) a mentálnej únavy (Mental fatigue). Horší funkčný stav bez 
ovplyvnenia depresiou viedol k zhoršeniu fyzickej únavy (Physical 
fatigue) a prítomnosť depresie samostatne viedla k zhoršeniu redukovanej 
motivácie (Reduced motivation). 
Limitáciou našej práce boli dáta založené na prierezovej štúdii. 
Uspokojivejšie vysvetlenie vzťahov medzi skúmanými premennými 
poskytnú dáta z longitudinálnej štúdie. Budúci výskum by sa mohol 
zamerať aj na porovnanie rôznych populácii pacientov s Parkinsonovou 
chorobou – pacientov vo včasnom alebo v pokročilom štádiu.
Aj výsledky tejto práce potvrdzujú, že nemotorické prejavy 
Parkinsonovej choroby sú často prítomné, postihujúce rôzne systémy a 
vedú k rôznym prejavom, či už k neuropsychiatrickým, senzorickým, alebo 
v oblasti autonómneho nervového systému. Vo všeobecnosti významnou 
mierou prispievajú k zhoršeniu kvality života už i tak zhoršenej 
prítomným samotným ochorením. V ére efektívneho manažmentu 
motorických prejavov sa tak nemotorické prejavy Parkinsonovej choroby 
stávajú významným faktorom vplývajúcim na každodenné činnosti. 128  ABOUT THE AUTHOR129
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